var title_f11_41_11920="Cutaneous melioidosis";
var content_f11_41_11920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous melioidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Purplish, palpable skin lesions in a case of melioidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bart Currie, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_41_11920=[""].join("\n");
var outline_f11_41_11920=null;
var title_f11_41_11921="Pelvic vertical shear injury";
var content_f11_41_11921=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pelvic vertical shear injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vertical shear injury with left sacral fracture, rami fractures, and associated left transverse acetabulum fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jim Fiechtl, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_41_11921=[""].join("\n");
var outline_f11_41_11921=null;
var title_f11_41_11922="Multiple tortuous pelvic veins";
var content_f11_41_11922=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F86201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F86201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Multiple tortuous pelvic veins in a patient with chronic pelvic pain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 211px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    48-year-old woman with chronic pelvic pain.",
"    <br/>",
"    A) Transvaginal ultrasound image shows multiple tubular structures.",
"    <br/>",
"    B) Color doppler of the same image shows flow in the tubular structures, compatible with multiple tortuous dilated pelvic veins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_41_11922=[""].join("\n");
var outline_f11_41_11922=null;
var title_f11_41_11923="Mucosal barrier gel: Drug information";
var content_f11_41_11923=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mucosal barrier gel: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/11/31923?source=see_link\">",
"    see \"Mucosal barrier gel: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7290545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Episil&reg;;",
"     </li>",
"     <li>",
"      Gelclair&reg; [DSC];",
"     </li>",
"     <li>",
"      Mucotrol&trade;;",
"     </li>",
"     <li>",
"      MuGard&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7303413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gastrointestinal Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7303465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Mucosal protection:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Episil&reg;: Apply 1-3 pumps to the oral cavity 2-3 times daily, or as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gelclair&reg;: Rinse, gargle, and spit 15 mL (1 single-use packet) mixed in water 3 times daily, or as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mucotrol&trade;: Slowly dissolve 1 wafer by swishing around in the mouth, 3 times daily, or as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MuGard&trade;: Rinse with 5 mL 4-6 times daily; may use up to 10 mL if needed to fully coat inside of month.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7303466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7303470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, oral [concentrate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gelclair&reg;: 15 mL/packet (15s [DSC]) [contains benzalkonium chloride, castor oil, propylene glycol, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel-forming wafer, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucotrol&trade;:  (21s, 45s) [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Episil&reg;:  (10 mL) [contains ethanol, propylene glycol, soy lecithin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MuGard&trade;:  (5 mL, 240 mL) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15901591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gelclair&reg;: U.S. availability expected in the first quarter of 2013",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7303467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gelclair&reg;, Mucotrol&trade;, MuGard&trade;: Avoid eating or drinking for at least 1 hour following treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Episil&reg;: Remove protective cap from pump and prime pump by pumping into a paper cloth until an even liquid stream develops; firmly press pump (1-3 times) to apply liquid stream to oral cavity, distribute to affected areas of mouth and wait for gel and protective film to form. Do not swallow. Wait 5 minutes after use before eating and drinking.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gelclair&reg;: Add 15 mL (1 single use packet) to water and stir (refer to product information for details); rinse around the mouth for a minimum of 1 minute (as long as possible) to coat the tongue, palate, throat, inside of cheeks, and all oral tissue thoroughly. Mixture should be gargled and spit out. If unable to rinse and gargle, apply directly to mouth using a sponge or swab. Do not swallow.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mucotrol&trade;:  Wafer should be swished around the mouth and allowed  to slowly dissolve.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MuGard&trade;: Gently pour 5 mL into mouth and rinse entire oral cavity for at least 1 minute (if rinsing is painful, spread throughout mouth by gently rotating head); may use up to 10 mL to coat entire oral cavity if needed. May spit or swallow excess rinse.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7303414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of oral mucosal pain caused by oral mucositis/stomatitis (resulting from chemotherapy or radiation therapy), irritation due to oral surgery, traumatic ulcers caused by braces/ill-fitting dentures or disease, diffuse aphthous ulcers (canker sores)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7303419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Postmarketing and/or case reports: Burning sensation in the mouth, mild inflammation and stinging of the oral cavity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7303415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Additional product-specific contraindications: Episil&reg;: Hypersensitivity to peanuts, soya, or peppermint oil",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7303416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy related issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sublingual medications: May decrease absorption of sublingually administered medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage from specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Episil&reg;: Contains alcohol (may cause irritation when applied), propylene glycol (may cause skin irritation), and peppermint oil (may cause allergic reaction).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gelclair&reg;, Mucotrol&trade;, MuGard&trade;: Avoid eating or drinking for at least 1 hour following use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Consult a physician if no improvement is seen after 7 days of use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F16061134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F16061132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7303469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor mucositis/stomatitis symptoms/severity",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7303563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adheres to the mucosal surface of mouth forming a protective film or coating over the irritated areas and lesions.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barber C, Powell R, Ellis A, et al, &ldquo;Comparing Pain Control and Ability to Eat and Drink With Standard Therapy vs Gelclair: A Preliminary, Double Centre, Randomized Controlled Trial on Patients With Radiotherapy-Induced Oral Mucositis,&rdquo;",
"      <i>",
"       Support Care Cancer",
"      </i>",
"      , 2007, 15(4):427-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11923/abstract-text/17131132/pubmed\" id=\"17131132\" target=\"_blank\">",
"        17131132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hita-Iglesias P, Torres-Lagares D, and Guti&eacute;rrez-P&eacute;rez JL, &ldquo;Evaluation of the Clinical Behavior of a Polyvinylpyrrolidone and Sodium Hyalonurate gel (Gelclair) in Patients Subjected to Surgical Treatment With CO2 Laser,&rdquo;",
"      <i>",
"       Int J Oral Maxillofac Surg",
"      </i>",
"      , 2006, 35(6):514-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11923/abstract-text/16497479/pubmed\" id=\"16497479\" target=\"_blank\">",
"        16497479",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Naidu MU, Ramana GV, Ratnam SV, et al, &ldquo;A Randomised, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy of MF 5232 (Mucotrol), a Concentrated Oral Gel Wafer, in the Treatment of Oral Mucositis,&rdquo;",
"      <i>",
"       Drugs R D",
"      </i>",
"      , 2005, 6(5):291-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11923/abstract-text/16128599/pubmed\" id=\"16128599\" target=\"_blank\">",
"        16128599",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vokurka S, Skardova J, Hruskova R, et al, &ldquo;The Effect of Polyvinylpyrrolidone-Sodium Hyaluronate Gel (Gelclair) on Oral Microbial Colonization and Pain Control Compared With Other Rinsing Solutions in Patients With Oral Mucositis After Allogeneic Stem Cells Transplantation,&rdquo;",
"      <i>",
"       Med Sci Monit",
"      </i>",
"      , 2011, 17(10):CR572-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11923/abstract-text/21959611/pubmed\" id=\"21959611\" target=\"_blank\">",
"        21959611",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9507 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-B32189B1BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_41_11923=[""].join("\n");
var outline_f11_41_11923=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7290545\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7303413\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7303465\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7303466\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7303470\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15901591\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7303467\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7303414\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7303419\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7303415\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7303416\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16061134\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16061132\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7303469\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7303563\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9507\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9507|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/11/31923?source=related_link\">",
"      Mucosal barrier gel: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_41_11924="Potassium gluconate: Patient drug information";
var content_f11_41_11924=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Potassium gluconate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20515?source=see_link\">",
"     see \"Potassium gluconate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/22/1379?source=see_link\">",
"     see \"Potassium gluconate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat low potassium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702770",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to potassium gluconate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703212",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Addison's disease, high potassium levels, bowel block, very bad kidney disease, slow moving GI (gastrointestinal) tract, or slow stomach clearing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If water pill is stopped, potassium will most often be stopped too. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696686",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid salt substitutes that have potassium, potassium-sparing diuretics, or potassium products.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10986 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-D7E3B57AC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_41_11924=[""].join("\n");
var outline_f11_41_11924=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012646\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012645\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012650\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012651\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012653\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012648\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012649\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012654\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012655\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20515?source=related_link\">",
"      Potassium gluconate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/22/1379?source=related_link\">",
"      Potassium gluconate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_41_11925="Mechanism platelet activation";
var content_f11_41_11925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Activation of platelets",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The various stimuli causing platelet activation act by signal transduction through receptors, ultimately increasing the free cytosolic Ca2+ level in platelets. Several calcium mobilization reactions interact with the receptors and regulate cytosolic free Ca2+. Adenosine triphosphate (ATP) is converted to cyclic adenosine monophosphate (cAMP) by the enzyme adenylate cyclase (AC); cAMP is broken down to AMP by the enzyme phosphodiesterase (PDE). When cAMP is elevated, for example by prostacyclin (PGI2) binding to a specific receptor and stimulating adenylate cyclase (AC), some Ca2+ is stored in the dense tubules, reducing cytosolic free Ca2+ and the level of platelet activation. Guanosine triphosphate (GTP) is converted to cGMP by guanylate cyclase (GC); cGMP is broken down by a PDE to produce guanosine monophosphate (GMP). When cGMP is elevated by stimulation of GC by NO, free cytosolic Ca2+ is reduced by inhibition from leaving the dense tubules. Thus, modulating free cytosolic Ca2+ can increase or decrease platelet activity. The final step in platelet-mediated thrombosis is the exposure/activation of the platelet glycoprotein IIb/IIIa fibrinogen receptor, which binds to fibrinogen to create a platelet aggregate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permision from Folts JD, Schafer AI, Loscalzo J, et al. J Am Coll Cardiol 1999; 33:295.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_41_11925=[""].join("\n");
var outline_f11_41_11925=null;
var title_f11_41_11926="Nasogastric tube removal";
var content_f11_41_11926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nasogastric tube removal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 575px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After placing an absorbant pad, gently remove the tape fixing the tube to the patient's nose. Use a catheter-tip syringe to flush the tube with 10 mL of air or normal saline solution to ensure the tube doesn't contain stomach contents that could irritate tissues during tube removal. Clamp the tube by folding it in your hand, then gently and steadily pull the tube out. Provide a tissue to the patient with which to clean and blow their nose, if needed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Springhouse. Lippincott's Visual Encyclopedia of Clinical Skills. Philadelphia: Wolters Kluwer Health, 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_41_11926=[""].join("\n");
var outline_f11_41_11926=null;
var title_f11_41_11927="Intermediate case 10";
var content_f11_41_11927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1110px;\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Intermediate case 10",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 99px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_41_11927=[""].join("\n");
var outline_f11_41_11927=null;
var title_f11_41_11928="The fetal biophysical profile";
var content_f11_41_11928=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The fetal biophysical profile",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/41/11928/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/41/11928/contributors\">",
"     Frank A Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/41/11928/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/41/11928/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/41/11928/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/41/11928/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/41/11928/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetal biophysical profile score (BPS or BPP) refers to the sonographic assessment of four discrete biophysical variables:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fetal movement",
"     </li>",
"     <li>",
"      Fetal tone",
"     </li>",
"     <li>",
"      Fetal breathing",
"     </li>",
"     <li>",
"      Amniotic fluid volume",
"     </li>",
"     <li>",
"      Results of nonstress testing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these five parameters is given a score of 0 or 2 points, depending upon whether specific criteria are met (",
"    <a class=\"graphic graphic_table graphicRef79813 \" href=\"UTD.htm?21/10/21675\">",
"     table 1",
"    </a>",
"    ). The presence of these biophysical variables implies absence of significant central nervous system",
"    <span class=\"nowrap\">",
"     hypoxemia/acidemia",
"    </span>",
"    at the time of testing. By comparison, a compromised fetus typically exhibits loss of accelerations of the fetal heart rate (FHR), decreased body and breathing movements, hypotonia, and, less acutely, decreased amniotic fluid volume.",
"   </p>",
"   <p>",
"    The clinical value of the cumulative fetal BPS is that it is noninvasive, easily learned and performed, and an accurate means for predicting the presence of significant fetal acidemia, which is the most common cause of fetal death or damage [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/1\">",
"     1",
"    </a>",
"    ]. Seventy to 90 percent of late fetal deaths display evidence of chronic or acute and chronic compromise prior to demise [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/2\">",
"     2",
"    </a>",
"    ]. Sonographic detection of signs of fetal compromise can allow appropriate intervention that ideally will prevent adverse fetal sequelae.",
"   </p>",
"   <p>",
"    Although the use of biophysical testing schemes to monitor high-risk pregnancies has become routine, this practice pattern has evolved with limited high quality scientific data to support its use [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/3\">",
"     3",
"    </a>",
"    ]. Moreover, there are no randomized trials on which to base recommendations for the best initial testing approach for specific types of high-risk pregnancies, the optimal timing of test initiation, the frequency of testing based on test results, conditions that may affect test results, and the effect of gestational age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ONTOGENY OF FETAL BIOPHYSICAL REGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ontogeny of fetal biophysical development follows a rigidly prescribed course. The initial step is cell differentiation, whereby cells acquire their unique characteristics. Differentiation and functional capacity usually occur nearly simultaneously. Specific functional entities develop as individual cells begin to interact with each other and come under local regulation. As they become enervated, these functional entities progressively come under the control of local, then regional, and finally central neuronal regulation. All biophysical activities are eventually regulated and controlled by discrete centers within the brain. The individual neurons within a given regulatory site always retain their sensitivity to local factors; however, they are also sensitive and responsive to feedback from peripheral sensors and to traffic generated within the brain. Modulating brain traffic first manifests as short sleep-wake cycles, then progresses to circadian cycles, and finally to consciousness cycles.",
"   </p>",
"   <p>",
"    The following principles derive from this ontogeny and are the basis for fetal biophysical monitoring:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any given biophysical variable reflects the integration of signals arising within the central nervous system. The presence of normally organized biophysical activity is reliable, presumptive evidence that the central nervous system is intact and not affected by pathological modulation.",
"     </li>",
"     <li>",
"      Neurons, with their high metabolic rate and demand, are exquisitely sensitive to local hypoxemia and ischemia. Pathological suppression of the neurons composing a given regulatory site due to hypoxemia results in loss of the normal features of a given biophysical activity.",
"     </li>",
"     <li>",
"      However, the absence or diminution of a given biophysical variable does not necessarily mean pathology is present. Normal suppression of a regulatory center can occur from intrinsic fetal rhythms, such as the deep stage of quiet sleep, or the presence of circulating agents that cause general suppression of the brain, such as transplacental passage of maternal sedatives and opiates.",
"     </li>",
"     <li>",
"      Progressive loss of brain regulation of biophysical activities results in regression to regional control and ultimately to local control (reverse ontogeny).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BIOPHYSICAL VARIABLES USED IN FETAL MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetal BPS is derived from assessment of five discrete biophysical variables (",
"    <a class=\"graphic graphic_table graphicRef79813 \" href=\"UTD.htm?21/10/21675\">",
"     table 1",
"    </a>",
"    ), which are regulated by discrete higher central nervous system centers. Four of these parameters: FHR accelerations in response to fetal movements (nonstress test), fetal breathing movements, generalized fetal movements, and fetal tone are acute variables since they are acutely affected by perturbations in fetal oxygenation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute variables",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of the acute variables for the fetal BPS was based upon their ease of measurement and the ability to objectively evaluate them using universally available equipment (eg, external FHR monitors and ultrasound imaging). Other fetal biophysical activities (eg, sucking, swallowing, micturition, eye movements) may serve equally well as markers of fetal health, but are not included because measurement is difficult and may be subjective.",
"   </p>",
"   <p>",
"    Each of the acute variables can be viewed as an indirect assessment of the integrity of the regulatory center since each acts as a peripheral transducer of central nervous system regulatory output. When a given variable is observed to be normal (eg, fetal breathing movements), the integrity of the regulatory center is ensured and the presence of a pathological factor, such as hypoxemia or acidemia, can be reliably excluded. In contrast, when a given acute variable is not normal, a differential diagnosis is always required. The most common innocuous cause of absence of a given acute variable is fetal state change and, most commonly, quiet sleep. Since the sensitivity to depth and duration of quiet sleep varies by discrete regulatory center, it is unusual to observe the absence of two or more variables as a consequence of quiet sleep alone. Extending the observation period to encompass the usual duration of sleep state cycles minimizes the possibility of confusion of pathological versus physiological causes of absent variable. The more variables are absent (ie, the lower the score), the less likely the change is due to sleep state. Similarly, the longer the absence of variables, the more likely the cause is due to a pathological influence.",
"   </p>",
"   <p>",
"    The acute variables function to enhance fetal development, but are not essential to maintaining fetal life, thus they are expendable in times of stress since they are energy dependent and increase fetal oxygen requirements. As an example, pharmacological paralysis of sheep fetuses to prevent fetal movement results in an abrupt fall in oxygen consumption by as much as 20 percent and a rise in fetal PO2 by as much as 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/4\">",
"     4",
"    </a>",
"    ]. Similarly in the human fetus, administration of a short acting curare (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19990?source=see_link\">",
"     pancuronium",
"    </a>",
"    ) to prevent fetal movement produces an immediate rise in fetal venous PO2 by as much as 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of fall in oxygen concentration necessary to abolish a given regulatory center output varies by center. The most oxygen sensitive centers are the cardioregulatory neurons controlling the coupling of fetal movement and heart rate acceleration, and the fetal breathing center neurons. The centers regulating fetal movement have a higher threshold than those for fetal breathing or FHR accelerations; the fetal tone center has the highest threshold. Thus, the acute fetal variables respond to hypoxemia in a predictable, physiologically based cascade: loss of fetal breathing movements and FHR acceleration, followed by decreased fetal movement, and finally loss of fetal tone. This phenomenon is of great clinical value since it allows for estimation of both the presence and severity of hypoxemia.",
"   </p>",
"   <p>",
"    The threshold of the various regulatory centers is not absolute, but can adjust over time. This effect is likely a result of adaptive response, which increases local oxygen supply, rather than the result of a true change in neuron oxygen requirements. Such compensatory responses include increased oxygen extraction, elevated fetal hemoglobin with increased oxygen carrying capacity, and redistribution of blood flow to favor brain perfusion. In some chronic fetal conditions, the acute biophysical variables may initially disappear and then reappear despite a low P02.",
"   </p>",
"   <p>",
"    The relationship between significant fetal acidemia and low BPS was inferred because the BPS was first described before it was possible to obtain antepartum fetal blood. Perinatal mortality (gross and corrected) and serious perinatal morbidity (nonreassuring FHR tracing in labor, low Apgar scores, neonatal seizures, admission to an intensive care unit, hypoxemic-ischemic encephalopathy, intrauterine growth restriction) increased significantly as the last BPS fell (",
"    <a class=\"graphic graphic_figure graphicRef78661 \" href=\"UTD.htm?25/15/25855\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In addition, the cord blood pH of infants delivered either vaginally or by cesarean birth demonstrated a direct relationship to last BPS (",
"    <a class=\"graphic graphic_figure graphicRef65562 \" href=\"UTD.htm?26/58/27565\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/9\">",
"     9",
"    </a>",
"    ]. An inverse relationship between last BPS and incidence of cerebral palsy has also been observed, and may or may not be related to antepartum asphyxia (",
"    <a class=\"graphic graphic_figure graphicRef54595 \" href=\"UTD.htm?41/6/42093\">",
"     figure 3",
"    </a>",
"    ). Long-term asphyxia leading to adverse neurologic outcomes such as cerebral palsy and intellectual disability appears to be significantly reduced in high-risk patients managed by fetal biophysical profile scoring compared to untested low-risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The advent of ultrasound guided intrauterine fetal blood sampling (cordocentesis) made it possible to measure the direct and immediate relationship between the BPS, fetal PO2, and fetal pH [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=see_link\">",
"     \"Fetal blood sampling\"",
"    </a>",
"    .) These studies, which include over 1000 paired observations, indicate a significant direct relationship between the BPS and mean umbilical venous pH and further demonstrate that, in the individual fetus, the BPS accurately predicts both the probability and severity of existing acidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Thus, the score is an accurate proxy for fetal acidosis. By comparison, the relationship between the BPS and fetal P02 is less precise. This is expected since P02 varies according to fetal compensatory adaptive responses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chronic variable",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fifth variable of the fetal BPS is amniotic fluid volume. Fetal urine is the predominant source of amniotic fluid from approximately the mid-second trimester (16 weeks). Fetal urine production is primarily dependent upon renal perfusion, which in turn reflects selective distribution of cardiac output. The fetus responds to sustained hypoxemia (asphyxia) by selective redistribution of its cardiac output, with preferential flow directed to the brain, heart, adrenals, and placenta at the expense of all other organ systems [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/888?source=see_link\">",
"     \"Physiology of amniotic fluid volume regulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This protective mechanism is reflex in origin and is initiated by specialized chemoreceptors in the aortic arch and carotid arteries. Hypoxemia-induced reflex redistribution of cardiac output results in diminished fetal urine production [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/16\">",
"     16",
"    </a>",
"    ]. Fetal swallowing, a major mechanism for removal of amniotic fluid, is a vegetative reflex and very resistant to the effects of hypoxemia. Therefore, the net effect of decreased urine production is a gradual reduction in the amount of amniotic fluid, ultimately leading to oligohydramnios and then anhydramnios.",
"   </p>",
"   <p>",
"    The time course for the evolution of oligohydramnios is usually relatively long. On average, it takes approximately 15 days for a fetus to progress from normal to reduced amniotic fluid volume (in the absence of membrane rupture) and 23 days to develop severe oligohydramnios [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/16\">",
"     16",
"    </a>",
"    ]. However, acute changes in amniotic fluid volume with rapid deterioration of the BPS have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is also important to recognize that the fetal effects of hypoxia-induced redistribution of cardiac output are not confined to the fetal kidney. Other signs of chronic hypoxemia presenting in the fetus and newborn, such as reduced fetal growth with brain sparing, can be attributed to effects from the compensatory cardiovascular reflex response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BIOPHYSICAL SCORE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H302708846\">",
"    <span class=\"h2\">",
"     Determination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The composite fetal BPS is derived from the four acute variables (FHR accelerations in response to fetal movements [nonstress test], fetal breathing movements, generalized fetal movements, fetal tone) and the single chronic variable (amniotic fluid volume). Each of these five variables have been evaluated independently and the normal characteristic defined (",
"    <a class=\"graphic graphic_table graphicRef79813 \" href=\"UTD.htm?21/10/21675\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/18\">",
"     18",
"    </a>",
"    ]. The scoring method used for each variable is binary, ie, the variable is either normal or abnormal; gradations of abnormality are not used. A normal variable is assigned a score of two and an abnormal variable a score of zero. The maximal score is",
"    <span class=\"nowrap\">",
"     10/10",
"    </span>",
"    and the minimum score is",
"    <span class=\"nowrap\">",
"     0/10.",
"    </span>",
"   </p>",
"   <p>",
"    A",
"    variable may be assigned a normal score as soon as it is observed. Since most fetuses will be normal and will demonstrate these biophysical activities, the usual time to complete a normal fetal BPS is less than five minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/19\">",
"     19",
"    </a>",
"    ]. The acute variables are subject to fetal sleep wake cycles; thus, continuous observation for at least 30 minutes must occur before the variable can be defined as absent (abnormal). In one ultrasound study of fetuses from uncomplicated pregnancies at 36 to 42 weeks of gestation, the mean duration of a fetal sleep (no somatic movements) was about 20 minutes, with an upper range of about 40 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The variables should be present and normal biophysical activities to be assigned a score of two. As an example, monotonous picket-fence breathing or gasping should not be considered normal breathing movements nor should seizures be counted as normal fetal limb movements [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We generally base evaluation of amniotic fluid volume on ultrasound measurement of the largest visible pocket. To score 2 points, the selected largest pocket must have a transverse diameter of at least 1 centimeter and a vertical pocket of at least 2 centimeters. However, other methods of amniotic fluid volume assessment can be used (eg, normal amniotic fluid index is 5 to 25 cm, normal single deepest vertical pocket is 2.1 to 8 cm). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31558?source=see_link\">",
"     \"Assessment of amniotic fluid volume\"",
"    </a>",
"    .) There is a significant inverse relationship between oligohydramnios and perinatal mortality and morbidity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14233?source=see_link&amp;anchor=H11#H11\">",
"     \"Oligohydramnios\", section on 'Prognosis and management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H302709240\">",
"    <span class=\"h2\">",
"     Modified biophysical profile",
"    </span>",
"    &nbsp;&mdash;&nbsp;The modified biophysical profile was developed to simplify the examination and reduce the time necessary to complete testing by focusing on those components of the profile that are most predictive of outcome. Assessment of amniotic fluid volume and nonstress testing appears to be as reliable a predictor of long-term fetal well-being as the full BPS [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/24\">",
"     24",
"    </a>",
"    ]. A normal modified biophysical profile will occur in 90 percent of pregnancies tested, thus it is necessary to proceed with a full biophysical evaluation in only a minority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/25\">",
"     25",
"    </a>",
"    ]. The rate of stillbirth within one week of a normal test is the same as with the full BPS, 0.8 per 1000 women tested [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H302709247\">",
"    <span class=\"h2\">",
"     Factors affecting test results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of antenatal corticosteroids can be associated with transient FHR and behavioral changes that typically return to baseline by day four after treatment. The most consistent FHR finding is a decrease in variability on days two and three [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. Fetal breathing and body movements are also commonly reduced, which may result in a lower biophysical profile score or nonreactive nonstress test [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. However, fetal blood flow velocity waveform patterns in the umbilical artery, middle cerebral artery, and ductus venosus do not appear to be affected [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/31,34,35\">",
"     31,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The behavioral changes may reflect a physiologic response of the brain to glucocorticoids. Alternatively, they may be a consequence of a transient increase in fetal vascular resistance and blood pressure, which has been demonstrated in animal studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. These findings should be considered within the total clinical picture when assessing a fetus for possible delivery because of a nonreassuring fetal evaluation (nonstress test or biophysical profile) after corticosteroid administration.",
"   </p>",
"   <p>",
"    The effect of subclinical infection on test results is controversial. Although the BPS is used to diagnose fetal infection or chorioamnionitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/38\">",
"     38",
"    </a>",
"    ], most studies have not found it to be a very sensitive test of subclinical infection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preterm labor may be associated with absence of fetal breathing movements. However, a systematic review found that data were inadequate to recommend monitoring fetal breathing for prediction of preterm delivery within 48 hours or seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are sparse data on the effect of fasting on BPS. A study that performed a BPS one hour after a meal and 10 to 12 hours after abstaining from food and drink in 30 women with uncomplicated pregnancies reported scores of",
"    <span class=\"nowrap\">",
"     &ge;8/10",
"    </span>",
"    for all postprandial tests, but two fasting tests were",
"    <span class=\"nowrap\">",
"     4/10",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     6/10;",
"    </span>",
"    both tests rose to",
"    <span class=\"nowrap\">",
"     10/10",
"    </span>",
"    after the mother ate a meal [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/44\">",
"     44",
"    </a>",
"    ]. Point reductions during fasting were primarily due to non-reactive NSTs and inadequate fetal breathing movements. It is difficult to draw any conclusion about the effect of fasting on the BPS in the clinical setting, given the small size of this study and the absence of indications for antepartum fetal assessment.",
"   </p>",
"   <p>",
"    Mild maternal anemia (mean hemoglobin 9.4",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    did not appear to affect the BPS [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H302709940\">",
"    <span class=\"h1\">",
"     INTERPRETATION, MANAGEMENT, OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;BPS results are interpreted as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       10/10",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       8/10",
"      </span>",
"      (includes 2 points for amniotic fluid): risk of developing fetal asphyxia within one week if no intervention is low (about",
"      <span class=\"nowrap\">",
"       1/1000).",
"      </span>",
"     </li>",
"     <li>",
"      6 or",
"      <span class=\"nowrap\">",
"       8/10",
"      </span>",
"      (0 points for amniotic fluid): when amniotic fluid volume is decreased, the risk of developing fetal asphyxia within one week if no intervention is increased at",
"      <span class=\"nowrap\">",
"       89/1000.",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       6/10",
"      </span>",
"      (includes 2 points for amniotic fluid): equivocal test, significant possibility of developing fetal asphyxia cannot be excluded. Repeat test within 24 hours to see if one of the absent acute variables returns to normal or deliver if at or near term.",
"     </li>",
"     <li>",
"      0 to",
"      <span class=\"nowrap\">",
"       4/10:",
"      </span>",
"      risk of fetal asphyxia within one week if no intervention is 91 to",
"      <span class=\"nowrap\">",
"       600/1000.",
"      </span>",
"      Delivery is usually indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The predictive value of the four ultrasound-monitored variables for assurance of fetal well-being is equivalent to that of a full BPS (four ultrasound variables and nonstress test) when the four variables are all normal. This was illustrated in a prospective study in which the nonstress test (NST) was only performed if the ultrasound score was less than 8 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/46\">",
"     46",
"    </a>",
"    ]. This modification reduced the need for NSTs in 95 percent of cases and the average testing time per patient without reducing the predictive value of the test.",
"   </p>",
"   <p>",
"    An NST should always be performed if any ultrasound monitored variable is 0. However, a BPS of",
"    <span class=\"nowrap\">",
"     8/10",
"    </span>",
"    by any combination of variables with or without the NST is as accurate as a score of",
"    <span class=\"nowrap\">",
"     10/10",
"    </span>",
"    for the prediction of fetal well-being as long as no points are deducted for amniotic fluid volume (eg, FM+FB+FT+AVF=8 or FM+FT+AVF+NST=8, where FM=fetal movement, FB=fetal breathing, FT=fetal tone, AVF=amniotic fluid volume).",
"   </p>",
"   <p>",
"    Although outcome data from large randomized studies are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/47\">",
"     47",
"    </a>",
"    ], observational studies have reported it to be accurate for predicting the absence of significant fetal acidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/48\">",
"     48",
"    </a>",
"    ] and comparable to the contraction stress test [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The probability of fetal acidemia is virtually nil when the score is normal (10 or 8 without oligohydramnios); the likelihood of fetal compromise and death rises as the cumulative score falls. The false negative rate (ie, fetal death within one week of a last test with a normal score) is not zero, but is exceedingly low (0.4 to 0.6 per 1000 live births) and is approximately 10 percent of the overall perinatal mortality for a high-risk population [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/50\">",
"     50",
"    </a>",
"    ]. False-negatives are likely due to acute insults such as sudden cord prolapse, fetomaternal hemorrhage, or abruptio placenta.",
"   </p>",
"   <p>",
"    The utility of biophysical fetal monitoring was demonstrated in a study of 44,828 biophysical profile tests in which the risk of fetal demise within one week of a normal test result (corrected for lethal congenital anomalies and unpredictable causes of demise) was 0.8 per 1000 women tested [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/50\">",
"     50",
"    </a>",
"    ]. This result compares favorably with all other means of antepartum fetal assessment. In two large observational studies including over 18,000 women, use of the BPS was associated with a 61 to 76 percent reduction in perinatal mortality (corrected) compared to historic controls [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the positive predictive value of the BPS for evidence of true fetal compromise (eg, a non-reassuring fetal heart tracing during labor, neonatal acidemia, or other markers of neonatal morbidity at the time of delivery) is only approximately 50 percent, with a negative predictive value greater than 99.9 percent. Therefore, it is important that the a priori risk of fetal compromise be elevated to improve the performance of a positive test result.",
"   </p>",
"   <p>",
"    The fetal BPS reaches maximal clinical efficacy when interpreted within the context of fetal age and maternal and obstetric factors. As an example, a normal score predicts no fetal compromise and allows for conservative management in a gravida with discrete high risk factors, such as diabetes mellitus or hypertension. This affords the fetus the advantage of continued intrauterine maturation and thereby reduces the risk of complications from prematurity. In contrast, an abnormal score in a similar high risk patient allows for weighing of relative fetal-to-neonatal risks and selection of delivery at a time when the balance shifts to greater fetal risk (",
"    <a class=\"graphic graphic_figure graphicRef78999 \" href=\"UTD.htm?20/27/20926\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A change in maternal condition will also affect application of the fetal BPS. The decision to intervene in a patient with worsening hypertension, for example, may depend less on the score and more on maternal risk. Similarly, the presence of a favorable cervix for induction may override the results of the BPS when the fetus is mature or postterm.",
"   </p>",
"   <p>",
"    Case reports and small series suggest that the BPS is less reliable in pregnancies complicated by severe preterm fetal growth restriction. As an example, in one study, 48 growth restricted fetuses less than 32 weeks of gestation with abnormal umbilical artery Doppler results underwent BPS daily and NSTs three times daily [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/52\">",
"     52",
"    </a>",
"    ]. Ten of 27 fetuses with BPS of 8 developed nonreassuring fetal tracings 3.5 to 24 hours after the BPS and the repeat BPS was 2 in all 10 of these fetuses; three died in utero, seven were delivered promptly and six of these neonates had acidemic umbilical artery blood gases at birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INDICATIONS AND FREQUENCY OF TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Obstetricians and Gynecologists (ACOG) recommends antepartum fetal surveillance of pregnancies in which the risk of antepartum fetal demise is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/53\">",
"     53",
"    </a>",
"    ]. An ACOG Practice Bulletin states that women with high-risk factors for significant fetal acidemia should undergo antepartum fetal surveillance with tests such as the BPS and nonstress test. Specific indications for antenatal fetal assessment are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of fetal assessment\", section on 'Indications for antenatal testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All of the ultrasound-monitored variables for the BPS can be observed as early as the first trimester, although characteristics of fetal behavior (breathing, tone, movement, as well as other fetal activities) change with advancing gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. The minimum gestational age for testing should reflect the lower limit that intervention with delivery would be considered. This age has gradually decreased and is now 24 to 25 weeks in most centers. Testing may be initiated at this gestational age if clinical conditions suggest early fetal compromise is likely; otherwise, testing is initiated when individual clinical circumstances warrant fetal monitoring. Initiating testing at 32 to 34 weeks of gestation is appropriate for most pregnancies at increased risk of stillbirth.",
"   </p>",
"   <p>",
"    A reassuring BPS (eg, BPS of 8 to 10) should be repeated periodically (weekly or twice weekly) until delivery when the high-risk condition persists. Some experts recommend more frequent testing intervals, with individualization based on the high-risk clinical setting (eg, early severe fetal growth restriction) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/56\">",
"     56",
"    </a>",
"    ]. Any significant deterioration in the clinical status (eg, worsening preeclampsia, decreased fetal activity) requires fetal reevaluation, regardless of the amount of time elapsed since the last test.",
"   </p>",
"   <p>",
"    Normal antepartum testing does not preclude the need for intrapartum fetal monitoring. Induction of labor may be attempted with abnormal antepartum testing as long as the FHR and contractions are monitored continuously and are reassuring. Cesarean delivery is indicated if there are repetitive late decelerations.",
"   </p>",
"   <p>",
"    Although the BPS test is typically used for antepartum fetal assessment, it can also be done intrapartum. However, its clinical utility in the intrapartum is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11928/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Criteria for the fetal biophysical profile score (BPS) are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef79813 \" href=\"UTD.htm?21/10/21675\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H302708846\">",
"       'Determination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The acute variables are subject to fetal sleep wake cycles; thus, continuous observation for at least 30 minutes must occur before the variable can be defined as absent. (See",
"      <a class=\"local\" href=\"#H302708846\">",
"       'Determination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A score of 8 to",
"      <span class=\"nowrap\">",
"       10/10",
"      </span>",
"      is reassuring of fetal well-being when amniotic fluid is normal; 6 to",
"      <span class=\"nowrap\">",
"       8/10",
"      </span>",
"      is concerning when amniotic fluid volume is decreased and requires increased monitoring or delivery,",
"      <span class=\"nowrap\">",
"       6/10",
"      </span>",
"      with normal amniotic fluid volume is an equivocal test result and should be repeated within 24 hours if the patient is not delivered; and 0 to",
"      <span class=\"nowrap\">",
"       4/10",
"      </span>",
"      suggests a high risk of fetal asphyxia within one week if the patient remains undelivered or no therapeutic intervention is undertaken. (See",
"      <a class=\"local\" href=\"#H302709940\">",
"       'Interpretation, management, outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend monitoring pregnancies at risk of fetal compromise (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We suggest using the biophysical score for monitoring because it is a noninvasive, easily applied, accurate means for predicting the presence of significant fetal acidemia. Testing should be performed one or more times per week, depending upon the clinical situation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Indications and frequency of testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The integration of the BPS into the management of high-risk obstetric patients has been associated with a significant reduction in perinatal mortality. The perinatal mortality in a high-risk patient managed according to the fetal BPS is significantly lower than the rate observed in contemporary untested low risk patients. (See",
"      <a class=\"local\" href=\"#H302709940\">",
"       'Interpretation, management, outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/1\">",
"      Morrison I. Perinatal mortality: basic considerations. Semin Perinatol 1985; 9:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/2\">",
"      Chamberlain P. Late fetal death--has ultrasound a role to play in its prevention? Ir J Med Sci 1991; 160:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/3\">",
"      Signore C, Freeman RK, Spong CY. Antenatal testing-a reevaluation: executive summary of a Eunice Kennedy Shriver National Institute of Child Health and Human Development workshop. Obstet Gynecol 2009; 113:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/4\">",
"      Rurak DW, Gruber NC. The effect of neuromuscular blockade on oxygen consumption and blood gases in the fetal lamb. Am J Obstet Gynecol 1983; 145:258.",
"     </a>",
"    </li>",
"    <li>",
"     Harman, CR, Menticoglou, S, Manning, FA. Fetal Oxygen Uptake: A test of placental reserve. Proc Soc Obstet Gynecol Canada 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/6\">",
"      Moore TR. Superiority of the four-quadrant sum over the single-deepest-pocket technique in ultrasonographic identification of abnormal amniotic fluid volumes. Am J Obstet Gynecol 1990; 163:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/7\">",
"      Manning FA, Morrison I, Lange IR, et al. Fetal assessment based on fetal biophysical profile scoring: experience in 12,620 referred high-risk pregnancies. I. Perinatal mortality by frequency and etiology. Am J Obstet Gynecol 1985; 151:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/8\">",
"      Manning FA. Fetal biophysical profile. Obstet Gynecol Clin North Am 1999; 26:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/9\">",
"      Vintzileos AM, Fleming AD, Scorza WE, et al. Relationship between fetal biophysical activities and umbilical cord blood gas values. Am J Obstet Gynecol 1991; 165:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/10\">",
"      Manning FA, Bondaji N, Harman CR, et al. Fetal assessment based on fetal biophysical profile scoring. VIII. The incidence of cerebral palsy in tested and untested perinates. Am J Obstet Gynecol 1998; 178:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/11\">",
"      Manning FA, Snijders R, Harman CR, et al. Fetal biophysical profile score. VI. Correlation with antepartum umbilical venous fetal pH. Am J Obstet Gynecol 1993; 169:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/12\">",
"      Ribbert LS, Snijders RJ, Nicolaides KH, Visser GH. Relationship of fetal biophysical profile and blood gas values at cordocentesis in severely growth-retarded fetuses. Am J Obstet Gynecol 1990; 163:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/13\">",
"      Chamberlain PF, Manning FA, Morrison I, et al. Ultrasound evaluation of amniotic fluid volume. I. The relationship of marginal and decreased amniotic fluid volumes to perinatal outcome. Am J Obstet Gynecol 1984; 150:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/14\">",
"      Phelan JP, Ahn MO, Smith CV, et al. Amniotic fluid index measurements during pregnancy. J Reprod Med 1987; 32:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/15\">",
"      Cohn HE, Sacks EJ, Heymann MA, Rudolph AM. Cardiovascular responses to hypoxemia and acidemia in fetal lambs. Am J Obstet Gynecol 1974; 120:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/16\">",
"      Nicolaides KH, Peters MT, Vyas S, et al. Relation of rate of urine production to oxygen tension in small-for-gestational-age fetuses. Am J Obstet Gynecol 1990; 162:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/17\">",
"      Sherer DM, Dayal AK, Schwartz BM, et al. Acute oligohydramnios and deteriorating fetal biophysical profile associated with severe preeclampsia. J Matern Fetal Med 1999; 8:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/18\">",
"      Manning FA, Platt LD, Sipos L. Antepartum fetal evaluation: development of a fetal biophysical profile. Am J Obstet Gynecol 1980; 136:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/19\">",
"      Manning FA, Baskett TF, Morrison I, Lange I. Fetal biophysical profile scoring: a prospective study in 1,184 high-risk patients. Am J Obstet Gynecol 1981; 140:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/20\">",
"      Pillai M, James D. Behavioural states in normal mature human fetuses. Arch Dis Child 1990; 65:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/21\">",
"      Patrick JE, Dalton KJ, Dawes GS. Breathing patterns before death in fetal lambs. Am J Obstet Gynecol 1976; 125:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/22\">",
"      Manning FA, Martin CB Jr, Murata Y, et al. Breathing movements before death in the primate fetus (Macaca mulatta). Am J Obstet Gynecol 1979; 135:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/23\">",
"      Romero R, Chervenak FA, Berkowitz RL, Hobbins JC. Intrauterine fetal tachypnea. Am J Obstet Gynecol 1982; 144:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/24\">",
"      Nageotte MP, Towers CV, Asrat T, Freeman RK. Perinatal outcome with the modified biophysical profile. Am J Obstet Gynecol 1994; 170:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/25\">",
"      Miller DA, Rabello YA, Paul RH. The modified biophysical profile: antepartum testing in the 1990s. Am J Obstet Gynecol 1996; 174:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/26\">",
"      Subtil D, Tiberghien P, Devos P, et al. Immediate and delayed effects of antenatal corticosteroids on fetal heart rate: a randomized trial that compares betamethasone acetate and phosphate, betamethasone phosphate, and dexamethasone. Am J Obstet Gynecol 2003; 188:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/27\">",
"      Mulder EJ, Derks JB, Visser GH. Antenatal corticosteroid therapy and fetal behaviour: a randomised study of the effects of betamethasone and dexamethasone. Br J Obstet Gynaecol 1997; 104:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/28\">",
"      Senat MV, Minoui S, Multon O, et al. Effect of dexamethasone and betamethasone on fetal heart rate variability in preterm labour: a randomised study. Br J Obstet Gynaecol 1998; 105:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/29\">",
"      Rotmensch S, Liberati M, Vishne TH, et al. The effect of betamethasone and dexamethasone on fetal heart rate patterns and biophysical activities. A prospective randomized trial. Acta Obstet Gynecol Scand 1999; 78:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/30\">",
"      Kelly MK, Schneider EP, Petrikovsky BM, Lesser ML. Effect of antenatal steroid administration on the fetal biophysical profile. J Clin Ultrasound 2000; 28:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/31\">",
"      Rotmensch S, Liberati M, Celentano C, et al. The effect of betamethasone on fetal biophysical activities and Doppler velocimetry of umbilical and middle cerebral arteries. Acta Obstet Gynecol Scand 1999; 78:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/32\">",
"      Katz M, Meizner I, Holcberg G, et al. Reduction or cessation of fetal movements after administration of steroids for enhancement of lung maturation. I. Clinical evaluation. Isr J Med Sci 1988; 24:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/33\">",
"      Wijnberger LD, Bilardo CM, Hecher K, et al. Effect of antenatal glucocorticoid therapy on arterial and venous blood flow velocity waveforms in severely growth-restricted fetuses. Ultrasound Obstet Gynecol 2004; 23:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/34\">",
"      Karaer C, Onderoglu L, Yigit N, et al. The effect of steroids on the biophysical profile and Doppler indices of umbilical and middle cerebral arteries in healthy preterm fetuses. Eur J Obstet Gynecol Reprod Biol 2001; 99:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/35\">",
"      Derks JB, Giussani DA, Jenkins SL, et al. A comparative study of cardiovascular, endocrine and behavioural effects of betamethasone and dexamethasone administration to fetal sheep. J Physiol 1997; 499 ( Pt 1):217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/36\">",
"      Koenen SV, Mecenas CA, Smith GS, et al. Effects of maternal betamethasone administration on fetal and maternal blood pressure and heart rate in the baboon at 0.7 of gestation. Am J Obstet Gynecol 2002; 186:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/37\">",
"      Smith RP, Miller SL, Igosheva N, et al. Cardiovascular and endocrine responses to cutaneous electrical stimulation after fentanyl in the ovine fetus. Am J Obstet Gynecol 2004; 190:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/38\">",
"      Vintzileos AM. Antepartum surveillance in preterm rupture of membranes. J Perinat Med 1996; 24:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/39\">",
"      Lewis DF, Adair CD, Weeks JW, et al. A randomized clinical trial of daily nonstress testing versus biophysical profile in the management of preterm premature rupture of membranes. Am J Obstet Gynecol 1999; 181:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/40\">",
"      Ghidini A, Salafia CM, Kirn V, et al. Biophysical profile in predicting acute ascending infection in preterm rupture of membranes before 32 weeks. Obstet Gynecol 2000; 96:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/41\">",
"      Del Valle GO, Joffe GM, Izquierdo LA, et al. The biophysical profile and the nonstress test: poor predictors of chorioamnionitis and fetal infection in prolonged preterm premature rupture of membranes. Obstet Gynecol 1992; 80:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/42\">",
"      Gauthier DW, Meyer WJ, Bieniarz A. Biophysical profile as a predictor of amniotic fluid culture results. Obstet Gynecol 1992; 80:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/43\">",
"      Honest H, Bachmann LM, Sengupta R, et al. Accuracy of absence of fetal breathing movements in predicting preterm birth: a systematic review. Ultrasound Obstet Gynecol 2004; 24:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/44\">",
"      Tug N, Ayvaci H, Tarhan N, et al. Effects of short-term maternal fasting in the third trimester of pregnancy on fetal biophysical profile and Doppler indices scores. Arch Gynecol Obstet 2011; 283:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/45\">",
"      Walach N. [Cancer in husband and wife--a report of 105 couples]. Harefuah 1991; 120:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/46\">",
"      Manning FA, Morrison I, Lange IR, et al. Fetal biophysical profile scoring: selective use of the nonstress test. Am J Obstet Gynecol 1987; 156:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/47\">",
"      Alfirevic Z, Neilson JP. Biophysical profile for fetal assessment in high risk pregnancies. Cochrane Database Syst Rev 2000; :CD000038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/48\">",
"      Gribbin C, James D. Assessing fetal health. Best Pract Res Clin Obstet Gynaecol 2004; 18:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/49\">",
"      Nageotte MP, Towers CV, Asrat T, et al. The value of a negative antepartum test: contraction stress test and modified biophysical profile. Obstet Gynecol 1994; 84:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/50\">",
"      Manning FA, Morrison I, Harman CR, et al. Fetal assessment based on fetal biophysical profile scoring: experience in 19,221 referred high-risk pregnancies. II. An analysis of false-negative fetal deaths. Am J Obstet Gynecol 1987; 157:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/51\">",
"      Manning FA. Fetal biophysical profile: a critical appraisal. Clin Obstet Gynecol 2002; 45:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/52\">",
"      Kaur S, Picconi JL, Chadha R, et al. Biophysical profile in the treatment of intrauterine growth-restricted fetuses who weigh &lt;1000 g. Am J Obstet Gynecol 2008; 199:264.e1.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Antepartum fetal surveillance. ACOG practice bulletin #9. American College of Obstetricians and Gynecologists, Washington, DC 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/54\">",
"      Jansen AH, Chernick V. Fetal breathing and development of control of breathing. J Appl Physiol 1991; 70:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/55\">",
"      Kurjak A, Andonotopo W, Hafner T, et al. Normal standards for fetal neurobehavioral developments--longitudinal quantification by four-dimensional sonography. J Perinat Med 2006; 34:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/56\">",
"      Manning FA. Dynamic ultrasound-based fetal assessment: the fetal biophysical profile score. Clin Obstet Gynecol 1995; 38:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/57\">",
"      Kim SY, Khandelwal M, Gaughan JP, et al. Is the intrapartum biophysical profile useful? Obstet Gynecol 2003; 102:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11928/abstract/58\">",
"      Sassoon DA, Castro LC, Davis JL, et al. The biophysical profile in labor. Obstet Gynecol 1990; 76:360.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5392 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-11633CD92E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_41_11928=[""].join("\n");
var outline_f11_41_11928=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ONTOGENY OF FETAL BIOPHYSICAL REGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BIOPHYSICAL VARIABLES USED IN FETAL MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute variables",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chronic variable",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BIOPHYSICAL SCORE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H302708846\">",
"      Determination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H302709240\">",
"      Modified biophysical profile",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H302709247\">",
"      Factors affecting test results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H302709940\">",
"      INTERPRETATION, MANAGEMENT, OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INDICATIONS AND FREQUENCY OF TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5392\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5392|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/15/25855\" title=\"figure 1\">",
"      Relationship between BPS and perinatal mortality and morbidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/58/27565\" title=\"figure 2\">",
"      Relationship between fetal pH and BPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/6/42093\" title=\"figure 3\">",
"      Relationship between cerebral palsy and last BPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/27/20926\" title=\"figure 4\">",
"      Risk of perinatal death in terms of BPS and GA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5392|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/10/21675\" title=\"table 1\">",
"      Components biophysical profile",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31558?source=related_link\">",
"      Assessment of amniotic fluid volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=related_link\">",
"      Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14233?source=related_link\">",
"      Oligohydramnios",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=related_link\">",
"      Overview of fetal assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/888?source=related_link\">",
"      Physiology of amniotic fluid volume regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_41_11929="Alteplase: Drug information";
var content_f11_41_11929=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alteplase: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/17/6420?source=see_link\">",
"    see \"Alteplase: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/2/12328?source=see_link\">",
"    see \"Alteplase: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Activase&reg;;",
"     </li>",
"     <li>",
"      Cathflo&reg; Activase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Activase&reg; rt-PA;",
"     </li>",
"     <li>",
"      Cathflo&reg; Activase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F132301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Thrombolytic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F132257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ST-elevation myocardial infarction (STEMI):",
"     </b>",
"     I.V. (Activase&reg;):",
"     <b>",
"      Note:",
"     </b>",
"     Manufacturer&rsquo;s labeling recommends 3-hour infusion regimen; however, accelerated regimen preferred by the ACC/AHA (Antman, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Accelerated regimen (weight-based):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Patients &gt;67 kg:",
"     </i>",
"     Total dose: 100 mg over 1.5 hours; administered as a 15 mg I.V. bolus over 1-2 minutes followed by infusions of 50 mg over 30 minutes, then 35 mg over 1 hour. Maximum total dose: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Patients &le;67 kg:",
"     </i>",
"     Infuse 15 mg I.V. bolus over 1-2 minutes followed by infusions of 0.75 mg/kg (not to exceed 50 mg) over 30 minutes then 0.5 mg/kg (not to exceed 35 mg) over 1 hour. Maximum total dose: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     All patients should receive 162-325 mg of chewable nonenteric coated aspirin as soon as possible and then daily. Administer concurrently with heparin 60 units/kg bolus (maximum: 4000 units) followed by continuous infusion of 12 units/kg/hour (maximum: 1000 units/hour) and adjust to aPTT target of 50-70 seconds (or 1.5-2 times the upper limit of control).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute massive or submassive pulmonary embolism (PE):",
"     </b>",
"     I.V. (Activase&reg;): 100 mg over 2 hours; may be administered as a 10 mg bolus followed by 90 mg over 2 hours as was done in patients with submassive PE (Konstantinides, 2002).",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended for submassive PE with minor RV dysfunction, minor myocardial necrosis, and no clinical worsening or low-risk PE (ie, normotensive, no RV dysfunction, normal biomarkers) (Jaff, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute ischemic stroke:",
"     </b>",
"     I.V. (Activase&reg;): Within 3 hours of the onset of symptom onset (labeled use)",
"     <b>",
"      or",
"     </b>",
"     within 3-4.5 hours of symptom onset (unlabeled use; del Zoppo, 2009; Hacke, 2008):",
"     <b>",
"      Note:",
"     </b>",
"     Initiation of anticoagulants (eg, heparin) or antiplatelet agents (eg, aspirin) within 24 hours after starting alteplase is not recommended; however, initiation of aspirin between 24-48 hours after stroke onset is recommended (Adams, 2007). Initiation of SubQ heparin (&le;10,000 units) or equivalent doses of low molecular weight heparin for prevention of DVT during the first 24 hours of the 3-4.5 hour window trial did not increase incidence of intracerebral hemorrhage (Hacke, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recommended total dose: 0.9 mg/kg (maximum total dose: 90 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Patients &le;100 kg:",
"     </i>",
"     Load with 0.09 mg/kg (10% of 0.9 mg/kg dose) as an I.V. bolus over 1 minute, followed by 0.81 mg/kg (90% of 0.9 mg/kg dose) as a continuous infusion over 60 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Patients &gt;100 kg:",
"     </i>",
"     Load with 9 mg (10% of 90 mg) as an I.V. bolus over 1 minute, followed by 81 mg (90% of 90 mg) as a continuous infusion over 60 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Central venous catheter clearance:",
"     </b>",
"     Intracatheter (Cathflo&reg; Activase&reg; 1 mg/mL):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients &lt;30 kg:",
"     </i>",
"     110% of the internal lumen volume of the catheter, not to exceed 2 mg/2 mL; retain in catheter for 0.5-2 hours; may instill a second dose if catheter remains occluded",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients &ge;30 kg:",
"     </i>",
"     2 mg (2 mL); retain in catheter for 0.5-2 hours; may instill a second dose if catheter remains occluded",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute peripheral arterial occlusion (unlabeled use):",
"     </b>",
"     Intra-arterial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Weight-based regimen:",
"     </i>",
"     0.001-0.02 mg/kg/hour (maximum dose: 2 mg/hour) (Semba, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Fixed-dose regimen:",
"     </i>",
"     0.12-2 mg/hour (Semba, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The ACC/AHA guidelines state that thrombolysis is an effective and beneficial therapy for those with acute limb ischemia (Rutherford categories I and IIa) of &lt;14 days duration (Hirsch, 2006). The optimal dosage and concentration has not been established; a number of intra-arterial delivery techniques are employed with continuous infusion being the most common (Ouriel, 2004). The Advisory Panel to the Society for Cardiovascular and Interventional Radiology on Thrombolytic Therapy recommends dosing of &le;2 mg/hour and concomitant administration of subtherapeutic heparin (aPTT 1.25-1.5 times baseline) (Semba, 2000). Duration of alteplase infusion dependent upon size and location of the thrombus; typically between 6-48 hours (Disini, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Complicated parapneumonic effusion (unlabeled use):",
"     </b>",
"     Intrapleural: 10 mg in 30 mL NS administered twice daily with a 1 hour dwell time for a total of 3 days; each dose followed in &gt;2 hours by intrapleural dornase alfa (Rahman, 2011). Some clinicians suggest consideration of fibrinolytic use when patients have failed at least 24 hours of chest tube drainage and are poor surgical candidates (Hamblin, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prosthetic valve thrombosis, right-sided (any size thrombus) or left-sided (thrombus area &lt;0.8 cm",
"      <sup>",
"       2",
"      </sup>",
"      ), or left-sided (thrombus area &ge;0.8 cm",
"      <sup>",
"       2",
"      </sup>",
"      ) when contraindications to surgery exist (unlabeled use)",
"     </b>",
"     (Alpert, 2003; Guyatt, 2012; Roudaut, 2003): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      High-dose regimen:",
"     </i>",
"     Load with 10 mg, followed by 90 mg over 90-180 minutes (without heparin during infusion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Low-dose regimen (preferred for very small adults):",
"     </i>",
"     Load with 20 mg, followed by 10 mg/hour for 3 hours (without heparin during infusion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     After successful administration of alteplase, heparin infusion should be introduced until warfarin achieves therapeutic INR (aortic: 3.0-4.0; mitral: 3.5-4.5) (Bonow, 2008). The 2012 ACCP guidelines for antithrombotic therapy make no recommendation regarding INR range after prosthetic valve thrombosis .",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F132279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/2/12328?source=see_link\">",
"      see \"Alteplase: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Central venous catheter clearance:",
"     </b>",
"     Intracatheter: Patients &lt;30 kg: 110% of the internal lumen volume of the catheter, not to exceed 2 mg/2 mL; retain in catheter for 0.5-2 hours; may instill a second dose if catheter remains occluded",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Complicated parapneumonic effusion (unlabeled use):",
"     </b>",
"     Intrapleural: Children &gt;3 months: 4 mg in 40 mL NS, first dose at time of chest tube placement with 1 hour dwell time, repeat every 24 hours for 3 days (total of 3 doses) or 0.1 mg/kg (maximum: 3 mg) in 10-30 mL NS, first dose after pigtail catheter (chest tube) placement, 0.75-1 hour dwell time, repeat every 8 hours for 3 days (total of 9 doses) (IDSA/PIDS, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F132258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15671450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F132234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [recombinant]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Activase&reg;: 50 mg, 100 mg [contains polysorbate 80; derived from or manufactured using Chinese hamster ovary  cells; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cathflo&reg; Activase&reg;: 2 mg [contains polysorbate 80; derived from or manufactured using Chinese hamster ovary cells]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F132219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F132237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Activase&reg;: ST-elevation MI or acute ischemic stroke: Administer bolus dose (prepared by one of three methods) over 1 minute followed by infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion: Remaining dose for STEMI, AIS, or total dose for acute pulmonary embolism may be administered as follows: Any quantity of drug not to be administered to the patient must be removed from vial(s) prior to administration of remaining dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg vial: Either PVC bag or glass vial and infusion set",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg vial: Insert spike end of the infusion set through the same puncture site created by transfer device and infuse from vial",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If further dilution is desired, may be diluted in equal volume of 0.9% sodium chloride or D",
"     <sub>",
"      5",
"     </sub>",
"     W to yield a final concentration of 0.5 mg/mL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cathflo&reg; Activase&reg;: Intracatheter: Instill dose into occluded catheter. Do not force solution into catheter. After a 30-minute dwell time, assess catheter function by attempting to aspirate blood. If catheter is functional, aspirate 4-5 mL of blood in patients &ge;10 kg or 3 mL in patients &lt;10 kg to remove Cathflo&reg; Activase&reg; and residual clots. Gently irrigate the catheter with NS. If catheter remains nonfunctional, let Cathflo&reg; Activase&reg; dwell for another 90 minutes (total dwell time: 120 minutes) and reassess function. If catheter function is not restored, a second dose may be instilled.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Parapneumonic effusion (unlabeled use): Intrapleural: Instill dose into chest tube and clamp drain. Although the optimum dwell time has not been determined, clinical trials more often have used either a 45 minute (Hawkins, 2004) or 1 hour (Rahman, 2011; St. Peter, 2009) dwell time; after dwell period, release clamp and connect chest tube to continuous suction.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14471277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Concentrations for some indications (eg, peripheral arterial occlusion) may require further dilution (eg, 0.1-0.2 mg/mL [Chan, 2001; Semba, 2000]) and a usual concentration may not be established.",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14471278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     0.5 mg/mL",
"     <b>",
"      or",
"     </b>",
"     1 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F132307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, sterile water for injection;",
"     <b>",
"      incompatible",
"     </b>",
"     with bacteriostatic water, LR;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Eptifibatide, lidocaine, metoprolol, propranolol.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Bivalirudin, dobutamine, heparin, morphine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dopamine, nitroglycerin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F132236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of ST-elevation myocardial infarction (STEMI) for the lysis of thrombi in coronary arteries; management of acute ischemic stroke (AIS); management of acute pulmonary embolism (PE)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommended criteria for treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     STEMI: Chest pain &ge;20 minutes duration, onset of chest pain within 12 hours of treatment (or within prior 12-24 hours in patients with continuing ischemic symptoms), and ST-segment elevation &gt;0.1 mV in at least two contiguous precordial leads or two adjacent limb leads on ECG or new or presumably new left bundle branch block (LBBB)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AIS: Onset of stroke symptoms within 3 hours of treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute pulmonary embolism: Age &le;75 years: Documented massive PE (defined as acute PE with sustained hypotension [SBP &lt;90 mm Hg for &le;15 minutes or requiring inotropic support], persistent profound bradycardia [HR &lt;40 bpm with signs or symptoms of shock], or pulselessness); alteplase may be considered for submassive PE with clinical evidence of adverse prognosis (eg, new hemodynamic instability, worsening respiratory insufficiency, severe RV dysfunction, or major myocardial necrosis) and low risk of bleeding complications.",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended for patients with low-risk PE (eg, normotensive, no RV dysfunction, normal biomarkers) or submassive acute PE with minor RV dysfunction, minor myocardial necrosis, and no clinical worsening (Jaff, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cathflo&reg; Activase&reg;: Restoration of central venous catheter function",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F132297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute ischemic stroke presenting 3-4.5 hours after symptom onset; acute peripheral arterial occlusion; infected parapneumonic effusion (with [adult] or without [pediatric] dornase alfa); prosthetic valve thrombosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F132309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Activase&reg; may be confused with Cathflo&reg; Activase&reg;, TNKase&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Alteplase may be confused with Altace&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       &ldquo;tPA&rdquo; abbreviation should not be used when writing orders for this medication; has been misread as TNKase (tenecteplase)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V.) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F132299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As with all drugs which may affect hemostasis, bleeding is the major adverse effect associated with alteplase. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the dosage administered, concurrent use of multiple agents which alter hemostasis, and patient predisposition. Rapid lysis of coronary artery thrombi by thrombolytic agents may be associated with reperfusion-related atrial and/or ventricular arrhythmia.",
"     <b>",
"      Note:",
"     </b>",
"     Lowest rate of bleeding complications expected with dose used to restore catheter function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Bruising (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: GI hemorrhage (5%), nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: GU hemorrhage (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Bleeding (0.5% major, 7% minor: GUSTO trial)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Bleeding at catheter puncture site (15.3%, accelerated administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Angioedema (orolingual), intracranial hemorrhage (0.4% to 0.87% when adult dose is &le;100 mg), retroperitoneal hemorrhage, pericardial hemorrhage, gingival hemorrhage, epistaxis, allergic reaction (anaphylaxis, anaphylactoid reactions, laryngeal edema, rash, and urticaria [&lt;0.02%])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Additional cardiovascular events associated",
"     <b>",
"      with use in STEMI:",
"     </b>",
"     AV block, cardiogenic shock, heart failure, cardiac arrest, recurrent ischemia/infarction, myocardial rupture, electromechanical dissociation, pericardial effusion, pericarditis, mitral regurgitation, cardiac tamponade, thromboembolism, pulmonary edema, asystole, ventricular tachycardia, bradycardia, ruptured intracranial AV malformation, seizure, hemorrhagic bursitis, cholesterol crystal embolization",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Additional events associated",
"     <b>",
"      with use in pulmonary embolism:",
"     </b>",
"     Pulmonary re-embolization, pulmonary edema, pleural effusion, thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Additional events associated",
"     <b>",
"      with use in stroke:",
"     </b>",
"     Cerebral edema, cerebral herniation, seizure, new ischemic stroke",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F132240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to alteplase or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Treatment of STEMI or PE:",
"     </b>",
"     Active internal bleeding; history of CVA; ischemic stroke within 3 months (Antman, 2004; Jaff, 2011); recent intracranial or intraspinal surgery or trauma; intracranial neoplasm; prior intracranial hemorrhage (Antman, 2004; Jaff, 2011); arteriovenous malformation or aneurysm; known bleeding diathesis; severe uncontrolled hypertension (listed as a relative contraindication in STEMI [Antman, 2004] and PE [Jaff, 2011] guidelines); suspected aortic dissection (Antman, 2004; Jaff, 2011); significant closed head or facial trauma (Antman, 2004; Jaff, 2011) within 3 months with radiographic evidence of bony fracture or brain injury (Jaff, 2011)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Treatment of acute ischemic stroke:",
"     </b>",
"     Evidence of intracranial hemorrhage or suspicion of subarachnoid hemorrhage on pretreatment evaluation; intracranial or intraspinal surgery within 3 months; stroke or serious head injury within 3 months; history of intracranial hemorrhage; uncontrolled hypertension at time of treatment (eg, &gt;185 mm Hg systolic or &gt;110 mm Hg diastolic); seizure at the onset of stroke; active internal bleeding; intracranial neoplasm; arteriovenous malformation or aneurysm; multilobar cerebral infarction (hypodensity &gt;",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     cerebral hemisphere; Adams, 2007); known bleeding diathesis including but not limited to current use of oral anticoagulants (unless INR &le;1.7 [Adams, 2007]), an INR &gt;1.7 (or PT &gt;15 seconds), administration of heparin within 48 hours preceding the onset of stroke with an elevated aPTT at presentation, or platelet count &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"     <b>",
"      Note:",
"     </b>",
"     Specific guidelines have been suggested for the patient currently receiving dabigatran (Alberts, 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Additional exclusion criteria within clinical trials:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Presentation &lt;3 hours after initial symptoms (NINDS, 1995): Time of symptom onset unknown, rapidly improving or minor symptoms, major surgery within 2 weeks, GI or urinary tract hemorrhage within 3 weeks, aggressive treatment required to lower blood pressure, glucose level &lt;50 or &gt;400 mg/dL, and arterial puncture at a noncompressible site or lumbar puncture within 1 week.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     Presentation 3-4.5 hours after initial symptoms (del Zoppo, 2009; ECASS-III; Hacke, 2008): Age &gt;80 years, time of symptom onset unknown, rapidly improving or minor symptoms, current use of oral anticoagulants regardless of INR, glucose level &lt;50 or &gt;400 mg/dL, aggressive intravenous treatment required to lower blood pressure, major surgery or severe trauma within 3 months, baseline National Institutes of Health Stroke Scale (NIHSS) score &gt;25, and history of both stroke and diabetes.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F132223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arrhythmias: Coronary thrombolysis may result in reperfusion arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: The total dose should not exceed 90 mg for acute ischemic stroke or 100 mg for acute myocardial infarction or pulmonary embolism. Doses &ge;150 mg associated with significantly increased risk of intracranial hemorrhage compared to doses &le;100 mg. Monitor all potential bleeding sites; if serious bleeding occurs, the infusion of alteplase and heparin should be stopped.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conditions that increase bleeding risk: For the following conditions, the risk of bleeding is higher with use of thrombolytics and should be weighed against the benefits of therapy: Recent  (within 10 days) major surgery (eg, CABG, obstetrical delivery, organ biopsy, pregnancy, previous puncture of noncompressible vessels), prolonged CPR with evidence of thoracic trauma, lumbar puncture within 1 week, cerebrovascular disease, recent gastrointestinal or genitourinary bleeding, recent trauma, hypertension (systolic BP &gt;175 mm Hg and/or diastolic BP &gt;110 mm Hg), high likelihood of left heart thrombus (eg, mitral stenosis with atrial fibrillation), acute pericarditis, subacute bacterial endocarditis, hemostatic defects including ones caused by severe renal or hepatic dysfunction, significant hepatic dysfunction, diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions, septic thrombophlebitis or occluded AV cannula at seriously infected site and/or any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of location.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; ST-elevation myocardial infarction (STEMI): Appropriate use: Follow standard management for STEMI while infusing alteplase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stroke: Appropriate use: Patients who present",
"     <b>",
"      within 3 hours",
"     </b>",
"     of stroke symptom onset should be treated with alteplase unless contraindications exist. A longer time window (",
"     <b>",
"      3-4.5 hours",
"     </b>",
"     after symptom onset) has now been formally evaluated and shown to be safe and efficacious for select individuals (del Zoppo, 2009; Hacke, 2008).Treatment of patients with minor neurological deficit or with rapidly improving symptoms is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticoagulants: Use with caution in patients receiving oral anticoagulants; increased risk of bleeding. In the treatment of acute ischemic stroke (AIS) within 3 hours of symptom onset, the current use of oral anticoagulants is a contraindication per the manufacturer. According to the AHA/ASA, the current use of oral anticoagulants producing an INR &gt;1.7 is a contraindication (Adams, 2007). It has been suggested that alteplase should be avoided in patients who are also receiving oral anticoagulants that do not or minimally affect the INR (eg, dabigatran) unless there is clear evidence of normal renal function (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute), the patient has not taken dabigatran in the past 48 hours, and normal coagulation testing (aPTT, INR, platelet count) (Alberts, 2012). When treating AIS 3-4.5 hours after symptom onset, the use of alteplase should be avoided with current use of any oral anticoagulant regardless of INR (del Zoppo, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aspirin: In the treatment of acute ischemic stroke, avoid aspirin for 24 hours following administration of alteplase; administration within 24 hours increases the risk of hemorrhagic transformation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heparin: Concurrent heparin anticoagulation may contribute to bleeding. In the treatment of acute ischemic stroke, concurrent use of anticoagulants was not permitted during the initial 24 hours of the &lt;3 hour window trial (NINDS, 1995). Initiation of SubQ heparin (&le;10,000 units) or equivalent doses of low molecular weight heparin for prevention of DVT during the first 24 hours of the 3-4.5 hour window trial was permitted and did not increase the incidence of intracerebral hemorrhage (Hacke, 2008). For acute PE, withhold heparin during the 2-hour infusion period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients with advanced age (eg, &gt;75 years); increased risk of bleeding. Acute ischemic stroke (within 3-4.5 hours after symptom onset): Patients &gt;80 years were excluded from the clinical trial (Hacke, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Use with caution in pregnancy; increased risk of bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cathflo&reg; Activase&reg;: When used to restore catheter function, use Cathflo&reg; cautiously in those patients with known or suspected catheter infections. Evaluate catheter for other causes of dysfunction before use. Avoid excessive pressure when instilling into catheter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Intramuscular injections and nonessential handling of the patient should be avoided. Venipunctures should be performed carefully and only when necessary. If arterial puncture is necessary, use an upper extremity vessel that can be manually compressed.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F132228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.  Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the therapeutic effect of Thrombolytic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Thrombolytic Agents may enhance the anticoagulant effect of Dabigatran Etexilate.  Management: Carefully monitor for bleeding.  Dabigatran Canadian labeling recommends avoiding use with thrombolytic agents. Consider avoiding alteplase treatment of acute ischemic stroke in patients receiving dabigatran (see full drug monograph for details).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Thrombolytic Agents may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Whenever possible, avoid use of drotrecogin within 3 days of a thrombolytic agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Thrombolytic Agents. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroglycerin: May decrease the serum concentration of Alteplase.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F132248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid cat's claw, dong quai, evening primrose, feverfew, red clover, horse chestnut, garlic, green tea, ginseng, ginkgo (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F132230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7872251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women. The risk of bleeding may be increased in pregnant women. Use during pregnancy is limited; administer to pregnant women only if the potential benefits justify the risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F132262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Activase Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $3356.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $6712.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Cathflo Activase Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (1): $129.06",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F132232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acute ischemic stroke (AIS): Baseline: Neurologic examination, head CT (without contrast), blood pressure, CBC, aPTT, PT/INR, glucose. During and after initiation: In addition to monitoring for bleeding complications, the 2007 AHA/ASA guidelines for the early management of AIS recommends the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Perform neurological assessments every 15 minutes during infusion and every 30 minutes thereafter for the next 6 hours, then hourly until 24 hours after treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If severe headache, acute hypertension, nausea, or vomiting occurs, discontinue the infusion and obtain emergency CT scan.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Measure BP every 15 minutes for the first 2 hours then every 30 minutes for the next 6 hours, then hourly until 24 hours after initiation of alteplase. Increase frequency if a systolic BP is &ge;180 mm Hg or if a diastolic BP is &ge;105 mm Hg; administer antihypertensive medications to maintain BP at or below these levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Obtain a follow-up CT scan at 24 hours before starting anticoagulants or antiplatelet agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central venous catheter clearance: Assess catheter function by attempting to aspirate blood.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     ST-elevation MI: Baseline: Blood pressure, serum cardiac biomarkers, CBC, PT/INR, aPTT. During and after initiation: Assess for evidence of cardiac reperfusion through resolution of chest pain, resolution of baseline ECG changes, preserved left ventricular function, cardiac enzyme washout phenomenon, and/or the appearance of reperfusion arrhythmias; assess for bleeding potential through clinical evidence of GI bleeding, hematuria, gingival bleeding, fibrinogen levels, fibrinogen degradation products, PT and aPTT.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F132235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Not routinely measured; literature supports therapeutic levels of 0.52-1.8 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Fibrinogen: 200-400 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Activated partial thromboplastin time (aPTT): 22.5-38.7 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prothrombin time (PT): 10.9-12.2 seconds",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F132242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actilyse (AE, AR, AT, AU, BD, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CN, CO, CY, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, HU, ID, IE, IL, IN, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PK, PL, PT, PY, QA, RU, SA, SC, SD, SE, SG, SL, SN, SY, TH, TN, TR, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Activacin (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F132222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initiates local fibrinolysis by binding to fibrin in a thrombus (clot) and converts entrapped plasminogen to plasmin",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F132239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &gt;50% present in plasma cleared ~5 minutes after infusion terminated, ~80% cleared within 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Clearance: Rapidly from circulating plasma (550-650 mL/minute), primarily hepatic; &gt;50% present in plasma is cleared within 5 minutes after the infusion is terminated, ~80% cleared within 10 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;A Comparison of Reteplase With Alteplase for Acute Myocardial Infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 337(16):1118-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/9340503/pubmed\" id=\"9340503\" target=\"_blank\">",
"        9340503",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Adams HP Jr, del Zoppo G, Alberts MJ, et al, \"Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology Affirms the Value of This Guideline as an Educational Tool for Neurologists,\"",
"      <i>",
"       Stroke",
"      </i>",
"      , 2007, 38(5):1655-711.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/17431204/pubmed\" id=\"17431204\" target=\"_blank\">",
"        17431204",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Alberts MJ, Bernstein RA, Naccarelli GV, et al, &ldquo;Using Dabigatran in Patients With Stroke: A Practical Guide for Clinicians,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2012, 43(1):271-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/22156688/pubmed\" id=\"22156688\" target=\"_blank\">",
"        22156688",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al, &ldquo;2008 Focused Update Incorporated into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 118(15):e523-661.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/18820172/pubmed\" id=\"18820172\" target=\"_blank\">",
"        18820172",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      B&ouml;ttiger BW, Bode C, Kern S, et al,&ldquo;Efficacy and Safety of Thrombolytic Therapy After Initially Unsuccessful Cardiopulmonary Resuscitation: A Prospective Clinical Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2001, 357(9268):1583-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/11377646/pubmed\" id=\"11377646\" target=\"_blank\">",
"        11377646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broderick J, Connolly S, Feldmann E, et al, &ldquo;Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2007, 38(6):2001-23. Available at  file://stroke.ahajournals.org/cgi/content/short/STROKEAHA.107.183689",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/17478736/pubmed\" id=\"17478736\" target=\"_blank\">",
"        17478736",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chan J, Rees CR, Song AK, et al, &ldquo;Usefulness of Catheter-Directed Thrombolysis Using Alteplase in Peripheral Vascular Occlusion,&rdquo; Proc (Bayl Univ Med Cent), 2001, 14(1):3-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/16369579/pubmed\" id=\"16369579\" target=\"_blank\">",
"        16369579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Colice GL, Curtis A, Deslauriers J, et al, &ldquo;Medical and Surgical Treatment of Parapneumonic Effusions: An Evidence-Based Guideline,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2000, 118(4):1158-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/11035692/pubmed\" id=\"11035692\" target=\"_blank\">",
"        11035692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Comerota AJ and Schmieder FA, &ldquo;Intraoperative Lytic Therapy: Agents and Methods of Administration,&rdquo;",
"      <i>",
"       Semin Vasc Surg",
"      </i>",
"      , 2001, 14(2):132-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/11400089/pubmed\" id=\"11400089\" target=\"_blank\">",
"        11400089",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      del Zoppo GJ, Saver JL, Jauch EC, et al, &ldquo;Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator: A Science Advisory From the American Heart Association/American Stroke Association,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2009, 40(8):2945-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/19478221/pubmed\" id=\"19478221\" target=\"_blank\">",
"        19478221",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Disini L, Wilson P, and Cockburn JF, &ldquo;Successful Intra-Arterial Alteplase Infusion is a Predictor of 12-Month Limb Survival in Patients With Lower Limb Arterial Occlusion,&rdquo;",
"      <i>",
"       Clin Radiol",
"      </i>",
"      , 2008, 63(6):636-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/18455554/pubmed\" id=\"18455554\" target=\"_blank\">",
"        18455554",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hacke W, Kaste M, Bluhmki E, et al, \"Thrombolysis With Alteplase 3 to 4.5 Hours After Acute Ischemic Stroke,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(13):1317-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/18815396/pubmed\" id=\"18815396\" target=\"_blank\">",
"        18815396",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamblin SE and Furmanek DL, &ldquo;Intrapleural Tissue Plasminogen Activator for the Treatment of Parapneumonic Effusion,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2010, 30(8):855-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/20653362/pubmed\" id=\"20653362\" target=\"_blank\">",
"        20653362",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hawkins JA, Scaife ES, Hillman ND, et al, &ldquo;Current Treatment of Pediatric Empyema,&rdquo;",
"      <i>",
"       Semin Thorac Cardiovasc Surg",
"      </i>",
"      , 2004, 16(3):196-200.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/15619185/pubmed\" id=\"15619185\" target=\"_blank\">",
"        15619185",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al, &ldquo;ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). A Collaborative Report of the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2006, 113(11):e463-654.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/16549646/pubmed\" id=\"16549646\" target=\"_blank\">",
"        16549646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jaff MR, McMurtry MS, Archer SL, et al, &ldquo;Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement from the American Heart Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(16):1788-830.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/21422387/pubmed\" id=\"21422387\" target=\"_blank\">",
"        21422387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Konstantinides S, Geibel A, Heusel G, et al, \"Heparin Plus Alteplase Compared With Heparin Alone in Patients With Submassive Pulmonary Embolism,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 347(15):1143-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/12374874/pubmed\" id=\"12374874\" target=\"_blank\">",
"        12374874",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kushner FG, Hand M, Smith SC, et al, &ldquo;2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(23):2205-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/19942100/pubmed\" id=\"19942100\" target=\"_blank\">",
"        19942100",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leonard MC and Shermock KM, &ldquo;Using Efficacy, Safety, and Cost Data to Support a Formulary Decision Regarding Thrombolytic Therapy,&rdquo;",
"      <i>",
"       Semin Vasc Surg",
"      </i>",
"      , 2001, 14(2):150-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/11400091/pubmed\" id=\"11400091\" target=\"_blank\">",
"        11400091",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lundergan CF, Reiner JS, McCarthy WF, et al, &ldquo;Clinical Predictors of Early Infarct-Related Artery Patency Following Thrombolytic Therapy: Importance of Body Weight, Smoking History, Infarct-Related Artery and Choice of Thrombolytic Regimen: The GUSTO-I Experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1998, 32(3):641-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/9741505/pubmed\" id=\"9741505\" target=\"_blank\">",
"        9741505",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Connor RE,  Brady W, Brooks SC, et al, &ldquo;Part 10: Acute Coronary Syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):787-817.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/20956226/pubmed\" id=\"20956226\" target=\"_blank\">",
"        20956226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ouriel K, &ldquo;Current Status of Thrombolysis for Peripheral Arterial Occlusive Disease,&rdquo;",
"      <i>",
"       Ann Vasc Surg",
"      </i>",
"      , 2002, 16(6):797-804.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/12391507/pubmed\" id=\"12391507\" target=\"_blank\">",
"        12391507",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ouriel K and Kandarpa K, &ldquo;Safety of Thrombolytic Therapy With Urokinase or Recombinant Tissue Plamsminogen Activator for Peripheral Arterial Occlusion: A Comprehensive Compilation of Published Work,&rdquo;",
"      <i>",
"       J Endovasc Ther",
"      </i>",
"      , 2004, 11(4):436-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/15298504/pubmed\" id=\"15298504\" target=\"_blank\">",
"        15298504",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ponec D, Irwin D, Haire WD, et al, &ldquo;Recombinant Tissue Plasminogen Activator (Alteplase) for Restoration of Flow in Occluded Central Venous Access Devices: A Double-Blind Placebo-Controlled Trial - The Cardiovascular Thrombolytic to Open Occluded Lines (COOL) Efficacy Trial,&rdquo;",
"      <i>",
"       J Vasc Interv Radiol",
"      </i>",
"      , 2001, 12(8):951-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/11487675/pubmed\" id=\"11487675\" target=\"_blank\">",
"        11487675",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rahman NM, Maskell NA, West A, et al, &ldquo;Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(6):518-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/21830966/pubmed\" id=\"21830966\" target=\"_blank\">",
"        21830966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Results of a Prospective, Randomised Trial Evaluating Surgery Versus Thrombolysis for Ischemia of the Lower Extremity. The STILE Trial,&rdquo;",
"      <i>",
"       Ann Surg",
"      </i>",
"      , 1994, 220(3):251-66; discussion 266-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/8092895/pubmed\" id=\"8092895\" target=\"_blank\">",
"        8092895",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Semba CP, Bakal CW, Calis KA, et al, &ldquo;Alteplase as an Alternative to Urokinase. Advisory Panel on Catheter-Directed Thrombolytic Therapy,&rdquo;",
"      <i>",
"       J Vasc Interv Radiol",
"      </i>",
"      , 2000, 11(3):279-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/10735420/pubmed\" id=\"10735420\" target=\"_blank\">",
"        10735420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      St Peter SD, Tsao, K, Harrison C, et al,  &ldquo;Thorascopic Decortication vs Tube Thoracostomy With Fibrinolysis for Empyema in Children: A Prospective, Randomized Trial,&rdquo;",
"      <i>",
"       J Pediatr Surg",
"      </i>",
"      , 2009, 44(1):106-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/19159726/pubmed\" id=\"19159726\" target=\"_blank\">",
"        19159726",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sugimoto K, Hofmann LV, Razavi MK, et al, &ldquo;The Safety, Efficacy, and Pharmacoeconomics of Low-Dose Alteplase Compared With Urokinase for Catheter-Directed Thrombolysis of Arterial and Venous Occlusions,&rdquo;",
"      <i>",
"       J Vasc Surg",
"      </i>",
"      , 2003, 37(3):512-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/12618684/pubmed\" id=\"12618684\" target=\"_blank\">",
"        12618684",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      The Gusto Angiographic Investigators, &ldquo;The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular Function, and Survival After Acute Myocardial Infarction,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(22):1615-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/8232430/pubmed\" id=\"8232430\" target=\"_blank\">",
"        8232430",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Thrombolysis in the Management of Lower Limb Peripheral Arterial Occlusion - A Consensus Document. Working Party on Thrombolysis in the Management of Limb Ischemia,&rdquo;",
"      <i>",
"       J Vasc Interv Radiol",
"      </i>",
"      , 2003, 14(9 Pt 2):337-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/14514841/pubmed\" id=\"14514841\" target=\"_blank\">",
"        14514841",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Tissue Plasminogen Activator for Acute Ischemic Stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(24):1581-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/7477192/pubmed\" id=\"7477192\" target=\"_blank\">",
"        7477192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Topol EJ, &ldquo;Reperfusion Therapy for Acute Myocardial Infarction With Fibrinolytic Therapy or Combination Reduced Fibrinolytic Therapy and Platelet Glycoprotein IIb/IIIa Inhibition: The GUSTO V Randomized Trial. GUSTO V Investigators,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2001, 357(9272):1905-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/11425410/pubmed\" id=\"11425410\" target=\"_blank\">",
"        11425410",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zacharias JM, Weatherston CP, Spewak CR, et al, &ldquo;Alteplase Versus Urokinase for Occluded Hemodialysis Catheters,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2003, 37(1):27-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/41/11929/abstract-text/12503929/pubmed\" id=\"12503929\" target=\"_blank\">",
"        12503929",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8478 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.244-3BAB8F1ACB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_41_11929=[""].join("\n");
var outline_f11_41_11929=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132252\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132253\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132301\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132257\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132279\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132258\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671450\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671451\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132234\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132219\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132237\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471277\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471278\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132307\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132236\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132297\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132309\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132299\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132240\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132223\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298716\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132228\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132248\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132230\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7872251\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132262\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322973\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132232\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132235\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132242\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132222\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132239\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8478\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8478|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/17/6420?source=related_link\">",
"      Alteplase: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/2/12328?source=related_link\">",
"      Alteplase: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_41_11930="Evaluation of the patient with established venous thrombosis";
var content_f11_41_11930=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the patient with established venous thrombosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/41/11930/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/41/11930/contributors\">",
"     Kenneth A Bauer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/41/11930/contributors\">",
"     Gregory YH Lip, MD, FRCPE, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/41/11930/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/41/11930/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/41/11930/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/41/11930/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/41/11930/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/41/11930/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presentations of venous thromboembolism (VTE) are deep vein thrombosis (DVT) of the lower extremity and pulmonary embolism. A risk factor for VTE, either hereditary or acquired, can now be identified in approximately 80 percent of patients. Furthermore, there is often more than one factor at play in a given patient. As an example, 50 percent of thrombotic events in patients with inherited thrombophilia are associated with an acquired risk factor (eg, surgery, pregnancy, oral contraceptives). In addition, some patients have more than one form of inherited thrombophilia and appear to be at greater risk for thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to the adult patient with",
"    <strong>",
"     established",
"    </strong>",
"    VTE will be discussed here, with emphasis upon clinical features and the indications for testing for an inherited or acquired cause of thrombophilia. The methods used to establish the presence of deep vein thrombosis of the lower extremity and the role of screening for thrombophilia in asymptomatic patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link\">",
"     \"Diagnosis of suspected deep vein thrombosis of the lower extremity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) clinical practice guidelines on diagnosis of acute venous thromboembolism, as well as other ATS guidelines, can be accessed through the ATS website at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Diagnostic and therapeutic approaches to the infant or child with VTE are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25033?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=see_link\">",
"     \"Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a minority of patients (17 and 32 percent in two large series) suspected of having DVT on clinical grounds actually have the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], illustrating the importance of objective testing (eg, compression ultrasonography) in order to minimize the likelihood of inappropriate anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link\">",
"     \"Diagnosis of suspected deep vein thrombosis of the lower extremity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptomatic patients without DVT have a variety of other disorders including popliteal cysts (Baker's cysts), muscle pulls and tears, and venous insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link&amp;anchor=H10#H10\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\", section on 'Differential diagnosis'",
"    </a>",
"    .) On the other hand, it should be appreciated that some high-risk patients (eg, after major surgery) develop DVT without local signs and symptoms. Such patients may present with pulmonary embolism, which can be fatal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diagnostic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic approach to the patient with established VTE is a two-step process:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first step consists of a careful history and physical examination combined with routine laboratory testing to characterize the presence and severity of the thrombotic condition and to determine whether any of the acquired causes of hypercoagulability (eg, malignancy) are present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H21#H21\">",
"       \"Overview of the causes of venous thrombosis\", section on 'Acquired thrombophilia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The second step is to decide whether to undertake laboratory screening for the presence of hereditary or acquired thrombophilia. The selection of patients for testing, the choice of tests to perform, and the timing of the tests are important issues to consider, and are discussed in the sections to follow (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Screening for inherited thrombophilia'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H23\">",
"       'Technical screening issues'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INITIAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete documentation of the circumstances surrounding the thrombotic event is important. In some cases, the cause may be obvious (eg, recent surgery or immobilization). The table reviews the major inherited and acquired conditions leading to thrombosis (",
"    <a class=\"graphic graphic_table graphicRef59759 \" href=\"UTD.htm?1/6/1132\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete thrombosis history includes the age of onset, location of prior thromboses, and results of objective diagnostic studies documenting thrombotic episodes. Objective confirmation of the diagnosis with imaging is important because of the nonspecific nature of the symptoms and signs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link\">",
"     \"Diagnosis of suspected deep vein thrombosis of the lower extremity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient should be carefully questioned concerning potential precipitating conditions proximate to the time of thrombosis, such as surgical procedures, trauma, pregnancy, heart failure, and immobility (",
"    <a class=\"graphic graphic_table graphicRef59759 \" href=\"UTD.htm?1/6/1132\">",
"     table 1",
"    </a>",
"    ). Women should be carefully questioned regarding use of oral contraceptives or hormone replacement therapy as well as their obstetric history. The presence of recurrent fetal loss suggests the possible presence of an inherited thrombophilia or antiphospholipid antibodies (aPL) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=see_link\">",
"     \"Obstetrical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Questions should include the presence of significant prothrombotic disorders (eg, collagen-vascular disease, myeloproliferative disease, atherosclerotic disease, nephrotic syndrome) and about the use of drugs which can induce aPL (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , phenothiazines) (",
"    <a class=\"graphic graphic_table graphicRef59759 \" href=\"UTD.htm?1/6/1132\">",
"     table 1",
"    </a>",
"    ). A positive family history is particularly important, since a well documented history of venous thrombosis in one or more first-degree relatives strongly suggests the presence of a hereditary prothrombotic disorder.",
"   </p>",
"   <p>",
"    The patient should be questioned about a past history of cancer, since recurrent thrombosis in spite of therapeutic anticoagulation with oral anticoagulants is common in patients with an occult neoplasm or recurrent cancer. Other findings that may suggest an underlying malignancy are constitutional symptoms such as loss of appetite, weight loss, fatigue, pain, hematochezia, hemoptysis, and hematuria.",
"   </p>",
"   <p>",
"    Since VTE may be the first manifestation of an underlying malignancy, rectal examination and stool testing for occult blood should be performed and women should undergo a pelvic examination. VTE may also be a manifestation of physical immobility and cardiovascular disorders such as heart failure. The presence or absence of these factors should be ascertained.",
"   </p>",
"   <p>",
"    The value of screening for malignancy in this setting is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link&amp;anchor=H7#H7\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Occult malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical exam",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the general physical examination, special attention should be directed to the vascular system, extremities (eg, looking for signs of superficial or deep vein thrombosis), chest, heart, abdominal organs, and skin (eg, skin necrosis, livedo reticularis).",
"   </p>",
"   <p>",
"    The actual physical signs of venous thrombosis can be quite unreliable. There may be pain and tenderness in the thigh along the course of the major veins (\"painful deep vein syndrome\") [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/7\">",
"     7",
"    </a>",
"    ]. Tenderness on deep palpation of the calf muscles is suggestive, but not diagnostic. Homans sign is also unreliable. The original description was based upon \"an increased resistance to dorsiflexion of the foot\" without associated discomfort or pain (despite the mistaken perpetuation of the latter symptom as part of Homans sign in textbooks). There is also the mistaken belief that eliciting Homans sign is dangerous; this concern is based upon a single case of pulmonary thromboembolism following calf pressure during a Doppler examination.",
"   </p>",
"   <p>",
"    Other signs and symptoms have variable sensitivity, specificity, and accuracy for DVT (confirmed by specific testing). In one series, the respective values for the following local symptoms were [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Edema &mdash; 97, 33, and 70 percent",
"     </li>",
"     <li>",
"      Pain &mdash; 86, 19, and 58 percent",
"     </li>",
"     <li>",
"      Warmth &mdash; 72, 48, and 62 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A reasonable pretest probability for the presence of DVT or PE can be obtained utilizing some of these signs and symptoms (eg, Wells score). This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link&amp;anchor=H19#H19\">",
"     \"Diagnosis of suspected deep vein thrombosis of the lower extremity\", section on 'Addition of pretest probability (Wells score)'",
"    </a>",
"    .) and (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link&amp;anchor=H25#H25\">",
"     \"Diagnosis of acute pulmonary embolism\", section on 'Algorithms'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The physical examination also may reveal signs of hepatic vein thrombosis (Budd-Chiari syndrome), such as ascites and hepatomegaly, or edema due to the nephrotic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31575?source=see_link\">",
"     \"Etiology of the Budd-Chiari syndrome\"",
"    </a>",
"    .) The hypercoagulable state associated with the nephrotic syndrome may be manifest as renal vein thrombosis, a usually asymptomatic complication unless associated with pulmonary embolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial laboratory evaluation in patients with VTE should include a complete blood count, coagulation studies, and serum chemistries including liver and renal function tests, and urinalysis. Consideration should be given to obtaining a prostate-specific antigen measurement in men over the age of 50.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevations in the hematocrit or platelet count, especially in patients with splenomegaly, should lead to consideration of one of the myeloproliferative disorders (eg, polycythemia vera, essential thrombocythemia) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/9\">",
"       9",
"      </a>",
"      ]. These disorders predispose patients to venous and arterial thrombotic events, particularly when the hematologic abnormalities (eg, hematocrit, platelet count) are not controlled by therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link&amp;anchor=H8#H8\">",
"       \"Overview of the myeloproliferative neoplasms\", section on 'Complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Secondary polycythemia or secondary (reactive) thrombocytosis may provide a clue to an underlying occult neoplasm that may be the predisposing factor to thrombosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24777?source=see_link&amp;anchor=H23#H23\">",
"       \"Diagnostic approach to the patient with polycythemia\", section on 'Acquired secondary polycythemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24681?source=see_link&amp;anchor=H6#H6\">",
"       \"Approach to the patient with thrombocytosis\", section on 'Reactive thrombocytosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anemia, leukopenia, and thrombocytopenia are often found in paroxysmal nocturnal hemoglobinuria, a rare hematologic disorder characterized by chronic intravascular hemolysis and a unique constellation of thrombotic complications. These occur almost exclusively in the abdominal venous network, including the mesenteric, hepatic, portal, splenic and renal veins, and the cerebral venous circulation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14121?source=see_link\">",
"       \"Clinical manifestations of paroxysmal nocturnal hemoglobinuria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The development of thrombosis and thrombocytopenia concurrent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      therapy should always prompt consideration of the diagnosis of heparin-induced thrombocytopenia, a disorder which has thrombotic sequelae in a significant proportion of cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"       \"Therapeutic use of heparin and low molecular weight heparin\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link&amp;anchor=H12#H12\">",
"       \"Heparin-induced thrombocytopenia\", section on 'Thrombosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An otherwise unexplained prolongation of the activated partial thromboplastin time, which does not correct on 1:1 dilution with normal plasma, is suggestive of the antiphospholipid syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H21#H21\">",
"       \"Clinical use of coagulation tests\", section on 'Prolonged clotting times'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"       \"Clinical manifestations of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examination of the blood smear may be diagnostic under some circumstances. If the blood smear shows evidence of red cell fragmentation or schistocytes (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"     picture 1",
"    </a>",
"    ), the differential diagnosis includes disseminated intravascular coagulation (DIC) and the thrombotic microangiopathies (thrombotic thrombocytopenic purpura-hemolytic uremic syndrome). Although bleeding is the most common coagulation problem in DIC, patients with malignancy can have a low-grade consumptive coagulopathy and develop venous or arterial thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link\">",
"     \"Hypercoagulable disorders associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another helpful finding on the blood smear is a leukoerythroblastic picture with nucleated red blood cells and immature white cells (",
"    <a class=\"graphic graphic_picture graphicRef68110 \" href=\"UTD.htm?29/43/30390\">",
"     picture 2",
"    </a>",
"    ). These findings suggest the possibility of bone marrow involvement by tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SCREENING FOR INHERITED THROMBOPHILIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thrombophilic state leading to venous thrombosis can be inherited or acquired:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Congenital/inherited",
"      </span>",
"      (eg, factor V Leiden, protein C deficiency)",
"     </li>",
"     <li>",
"      Acquired (eg, immobilization after orthopedic surgery, trauma)",
"     </li>",
"     <li>",
"      Associated with systemic disease (eg, malignancy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One (or more) of these predisposing factors can now be identified in approximately 80 percent of patients (",
"    <a class=\"graphic graphic_table graphicRef59759 \" href=\"UTD.htm?1/6/1132\">",
"     table 1",
"    </a>",
"    ). An inherited thrombophilia can be identified in 24 to 37 percent of unselected patients with DVT (compared with 10 percent of controls) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/10-12\">",
"     10-12",
"    </a>",
"    ] and in the majority of patients with familial thrombosis (",
"    <a class=\"graphic graphic_table graphicRef68916 \" href=\"UTD.htm?9/42/9899\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all of the available data on the inherited thrombophilic states (eg, factor V Leiden) are from Caucasian populations and very little information is available for non-Caucasian populations. The relative frequency of the different inherited thrombophilias is illustrated by the following observations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a Spanish study of 2132 consecutive unselected patients with VTE, 12.9 percent had an anticoagulant protein deficiency (7.3 percent with protein S, 3.2 percent with protein C, and 0.5 percent with antithrombin); in addition, 4.1 percent had antiphospholipid antibodies (aPL) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/11\">",
"       11",
"      </a>",
"      ]. There was no testing for factor V Leiden or the prothrombin gene mutation.",
"     </li>",
"     <li>",
"      An English report evaluated 570 patients with VTE in whom aPL, malignancy, and mesenteric or cerebral vein thrombosis were excluded [",
"      <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/12\">",
"       12",
"      </a>",
"      ]. Among 73 patients who had undergone recent surgery, 11 (15 percent) had an inherited thrombophilia, mostly factor V Leiden and protein S deficiency. Among 157 patients with an idiopathic VTE, 51 (32 percent) had an inherited thrombophilia: 17 percent factor V Leiden; 5 percent prothrombin gene mutation; 4 percent antithrombin deficiency, 7 percent protein S deficiency, and 0.7 percent protein C deficiency.",
"     </li>",
"     <li>",
"      In other series of patients with idiopathic VTE, the frequency of factor V Leiden was 21 to 24 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. Comparable values in controls were 5 to 6 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"       \"Activated protein C resistance and factor V Leiden\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The prothrombin gene mutation has been found in approximately 5 to 8 percent of patients with DVT, compared with 2 to 2.5 percent of controls [",
"      <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/13,16\">",
"       13,16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=see_link\">",
"       \"Prothrombin gene mutation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prior to the discovery of factor V Leiden and the prothrombin gene mutation, screening to identify one of the less common anticoagulant protein deficiencies was restricted to patients with recurrent or familial thrombosis. However, the discovery of the more common mutations and testing for aPL have substantially increased the likelihood of identifying a coagulation abnormality predisposing to thrombosis to 30 to 40 percent (",
"    <a class=\"graphic graphic_table graphicRef68916 \" href=\"UTD.htm?9/42/9899\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Multiple risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been estimated that 1 to 2 percent of patients with an idiopathic VTE have combined mutations. Such patients are at significantly increased risk for a",
"    <strong>",
"     first",
"    </strong>",
"    episode of VTE as compared with patients with heterozygosity for factor V Leiden or the prothrombin gene mutation, although they may not be at increased risk for VTE",
"    <strong>",
"     recurrence",
"    </strong>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of an acquired thrombophilic risk factor (eg, pregnancy and the puerperium, oral contraceptives, hormone replacement therapy, surgery, malignancy) should not preclude screening for an inherited thrombophilic disorder, since these acquired risk factors frequently trigger VTE in subjects with hereditary prothrombotic disorders (",
"    <a class=\"graphic graphic_table graphicRef72836 \" href=\"UTD.htm?43/18/44331\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef82188 \" href=\"UTD.htm?27/7/27771\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link&amp;anchor=H16#H16\">",
"     \"Activated protein C resistance and factor V Leiden\", section on 'Combined inherited defects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Upper extremity thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data as to whether patients presenting with upper extremity thrombosis have an increased prevalence of hereditary defects, with an indwelling venous catheter being the most common acquired risk factor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link\">",
"     \"Catheter-induced upper extremity venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=see_link\">",
"     \"Primary (spontaneous) upper extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two studies in patients with thrombosis of the upper extremity suggested that the incidence of thrombophilia may be as high as 26 to 42 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, in two other studies the incidence of hypercoagulable states (12 and 17 percent) was similar to that in controls [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], and the rate of recurrence was not increased in those with factor V Leiden or the prothrombin mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/25\">",
"     25",
"    </a>",
"    ]. It is presently unclear as to whether it is reasonable to evaluate patients with spontaneous upper extremity thrombosis for the presence of a hypercoagulable state.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Arterial thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete testing is not justified in patients presenting with arterial thrombosis, since hereditary thrombophilia is principally a risk factor only for venous thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/17\">",
"     17",
"    </a>",
"    ]. These patients should be specifically tested for the presence of antiphospholipid antibodies (aPL). As noted above, results of the complete blood count should help in diagnosing patients with hematologic disorders associated with an increased incidence of arterial thrombosis (eg, essential thrombocythemia, polycythemia vera).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     When not to screen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary prothrombotic disorders have not been found at increased frequency in patients who develop thrombosis in a number of clinical settings. Therefore, screening is not routinely recommended for unselected patients with thrombosis and the following [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recent major surgery, trauma, or immobilization",
"     </li>",
"     <li>",
"      Active malignancy",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus",
"     </li>",
"     <li>",
"      Inflammatory bowel disease",
"     </li>",
"     <li>",
"      Myeloproliferative disorders",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      -induced thrombocytopenia with thrombosis",
"     </li>",
"     <li>",
"      Preeclampsia at term",
"     </li>",
"     <li>",
"      Retinal vein thrombosis",
"     </li>",
"     <li>",
"      Upper limb venous thrombosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is currently no consensus regarding whom to test for the inherited thrombophilias. The pros and cons for routine testing are discussed below for completeness, followed by our recommendations. Most of the available data on this subject apply to patients with DVT of the lower extremity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ARGUMENTS AGAINST SCREENING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been argued that testing of all or most patients with an initial episode of VTE should not lead to a change in anticoagulant management, is costly (both the testing as well the potential need for additional consultations), and is therefore not cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with an initial episode of idiopathic (ie, unprovoked) VTE, routine testing for an inherited thrombophilic defect would be warranted if an alteration in the type or duration of initial anticoagulant therapy or the need for long-term antithrombotic therapy was indicated based upon the results of such testing.",
"   </p>",
"   <p>",
"    Two separate issues require consideration in answering this question. The first is whether the VTE recurrence risk differs between those having or not having an inherited thrombophilic defect during either the initial three to six months of anticoagulant therapy or during long-term anticoagulant therapy. This was addressed in a review of results from the ELATE trial, in which the probability of VTE recurrence for those with one or more inherited thrombophilic defects was the same as, or lower than, the recurrence rate in those with no abnormality during the entire length of the study, from three months through more than three years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The second issue is whether the recurrence rate after initial anticoagulant therapy is different among \"usual\" patients (ie, not the rare patients with very positive family histories) with a first unprovoked VTE with or without an inherited thrombophilia following discontinuation of anticoagulation. This issue was addressed in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three different studies of patients with a first episode of idiopathic VTE found no difference in recurrence rates in patients with or without factor V Leiden, the prothrombin gene mutation, a coagulation protein deficiency, or a positive family history for VTE [",
"      <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/12,13,31\">",
"       12,13,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients enrolled in the Leiden Thrombophilia Study who sustained a first idiopathic DVT, the risk of recurrent venous thrombosis in those with inherited thrombophilia",
"      <span class=\"nowrap\">",
"       (3.4/100",
"      </span>",
"      patient-years) was not significantly different from the recurrence risk in those without an underlying thrombophilic defect",
"      <span class=\"nowrap\">",
"       (3.2/100",
"      </span>",
"      patient-years, HR 1.2; 95% CI 0.7-2.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective analysis in 197 patients with VTE recurrence and 324 controls investigated whether screening for thrombophilia reduced the subsequent risk of recurrent VTE by virtue of alterations in anticoagulation resulting from such testing [",
"      <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/29\">",
"       29",
"      </a>",
"      ]. The odds ratio for VTE recurrence in tested versus non-tested patients was 1.2 (95% CI 0.9-1.8), and did not differ after correction for age, sex, family history, or presence of clinical risk factors. The authors concluded that thrombophilia testing in patients with a first episode of VTE did not reduce the incidence of subsequent recurrence in clinical practice.",
"     </li>",
"     <li>",
"      In a survey of 2000 consecutive patients who underwent thrombophilia testing, a subsequent questionnaire sent to the clinicians ordering these tests revealed that, in 77 percent of the patients, results of the testing did not alter management of that particular patient [",
"      <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis searched the available literature for studies that assessed rates of VTE in individuals with a history of VTE who were tested for FVL or prothrombin G20210A or in family members of individuals with these mutations. The authors concluded that it is unknown whether testing for FVL or prothrombin G20210A improves outcomes in adults with VTE or in family members of those with a mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the face of the available information, authors for the 2008 ACCP Guidelines have made the following statement about the presence of hereditary thrombophilia in this regard [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/35\">",
"     35",
"    </a>",
"    ]: \"The presence of hereditary thrombophilia has not been used as a major factor to guide duration of anticoagulation for VTE in these guidelines because evidence from prospective studies suggests that these factors are not major determinants of the risk of recurrence.\" A similar statement appears in the 2012 ACCP Guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/36\">",
"     36",
"    </a>",
"    ]. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link&amp;anchor=H2406396#H2406396\">",
"     \"Activated protein C resistance and factor V Leiden\", section on 'Risk of recurrent DVT'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Screening for hyperhomocysteinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data supporting a change in the duration or type of therapy for a patient with hyperhomocysteinemia and a past history of VTE, since hyperhomocysteinemia may be a marker of thrombotic disease rather than a cause [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/37\">",
"     37",
"    </a>",
"    ]. Results of a number of randomized, placebo-controlled trials of supplementation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , pyridoxine, and vitamin B12 indicate that such treatment did not significantly reduce the incidence of recurrent VTE events in patients with hyperhomocysteinemia.",
"   </p>",
"   <p>",
"    In addition, results from the Leiden MEGA study indicate that the presence of the T-variant of the common methylenetetrahydrofolate reductase (MTHFR) 677C&mdash;&gt;T polymorphism, which mildly increases homocysteine levels, is not associated with an increased risk for venous thrombosis (OR 0.99, 95% CI 0.91-1.08) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to these results, there is no clinical rationale for measurement of plasma homocysteine levels or for assaying for presence of the MTHFR 677C&mdash;&gt;T variant when screening for the risk of VTE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of homocysteine\", section on 'Screening for hyperhomocysteinemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Additional screening issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician who considers ordering screening tests for thrombophilia should be aware of the following issues [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening tests only infrequently identify patients with defects carrying specific management implications (eg, higher risk thrombophilias such as antithrombin deficiency or the presence of multiple thrombophilic defects)",
"     </li>",
"     <li>",
"      There is the potential for overaggressive management of the patient",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      asymptomatic affected relatives, resulting in overtreatment with hemorrhagic complications",
"     </li>",
"     <li>",
"      The cost of",
"      <span class=\"nowrap\">",
"       testing/consultations",
"      </span>",
"      can be considerable",
"     </li>",
"     <li>",
"      There is the potential for creation of undue anxiety in the patient",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      family members",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, it has been suggested that, when thrombophilia testing is considered, management decisions based on test results should be clear BEFORE the tests are performed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ARGUMENTS FOR SCREENING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Others have made the case in favor of testing after an initial episode of idiopathic VTE. The following arguments have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple prothrombotic defects (eg, homozygosity or compound heterozygosity for an inherited thrombophilic defect) are found in approximately 1 to 2 percent of patients presenting with an initial idiopathic VTE [",
"      <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. This increases the risk of recurrence and places patients in an even higher risk group that may alter management, particularly when additional acquired prothrombotic stresses are present (eg, surgery, pregnancy, immobilization) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/41,43\">",
"       41,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most clinicians recommend screening of family members of affected individuals, particularly when issues of oral contraception and pregnancy are involved, since there is an increased risk of VTE if such patients also have one or more inherited forms of thrombophilia (",
"      <a class=\"graphic graphic_table graphicRef72836 \" href=\"UTD.htm?43/18/44331\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef82188 \" href=\"UTD.htm?27/7/27771\">",
"       table 4",
"      </a>",
"      ). If screening is not offered to patients with thrombosis, asymptomatic relatives of patients with hereditary thrombophilia will be denied the benefits of knowing their risk for VTE in these and other high-risk settings [",
"      <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/28,44,45\">",
"       28,44,45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A study of 2479 relatives of 877 selected probands with thrombosis and a thrombophilic defect suggested differences in thrombotic risk among relatives with various inherited thrombophilias. The following observations were made [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk for a first DVT was 1.52 to 1.90",
"      <span class=\"nowrap\">",
"       percent/year",
"      </span>",
"      for relatives with deficiencies of antithrombin, protein C, or protein S (the high-risk group). Relatives with no thrombophilic defects had an incidence of 0.05",
"      <span class=\"nowrap\">",
"       percent/year.",
"      </span>",
"     </li>",
"     <li>",
"      The risk for a first DVT was 0.34 to 0.49",
"      <span class=\"nowrap\">",
"       percent/year",
"      </span>",
"      for those with factor V Leiden, the prothrombin gene mutation, or elevated levels of factor VIII (the low-risk group).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The data suggest that screening of family members of affected individuals might be restricted to those with deficiencies of antithrombin, protein C, and protein S.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Suggested approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;We believe that testing for an inherited thrombophilia has been prematurely adopted in routine medical practice. There is little evidence that the identification of inherited thrombophilias should influence the duration of anticoagulant therapy for patients with venous thromboembolism or that testing asymptomatic affected relatives leads to improved outcomes. Further, there are no randomized controlled trials that have assessed the benefits of testing for thrombophilia on the risk of recurrent VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We are not in favor of \"reflex\" screening for the inherited thrombophilias. However, patients with a strong family history of VTE should undergo testing for the five major inherited thrombophilic defects and their first degree relatives should be considered for screening. For other patients, we discuss the pros and cons of testing, explaining that their management is unlikely to be influenced by the discovery of an underlying thrombophilia. However, we take into account the desires of the patient and perhaps the referring clinician.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deficiency of protein C, protein S and antithrombin &mdash; These disorders are collectively found in 8 to 13 percent of unselected patients with an initial episode of VTE [",
"      <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/11,48\">",
"       11,48",
"      </a>",
"      ]. The likelihood of identifying these defects is increased several-fold by screening only patients with initial thrombosis occurring prior to age 50, a family history of venous thromboembolism, or recurrent thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/48\">",
"       48",
"      </a>",
"      ]. We also recommend consideration of screening when thrombosis occurs in association with oral contraceptive use or pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/19,20\">",
"       19,20",
"      </a>",
"      ], in unusual vascular beds such as portal, hepatic, mesenteric, or cerebral vein thrombosis, and in patients with a history of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      -induced skin necrosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link\">",
"       \"Protein C deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Factor V Leiden, the prothrombin gene mutation, antiphospholipid antibodies &mdash; We recommend consideration of testing of Caucasian patients presenting with an initial idiopathic episode of VTE prior to age 50 and all women with events associated with hormone therapy. Factor V Leiden and the prothrombin gene mutation have been identified in approximately 1 percent of the general African American population, such that these abnormalities will be identified relatively infrequently in this population of patients with idiopathic VTE. In the non-Caucasian population, we therefore recommend testing for lupus",
"      <span class=\"nowrap\">",
"       anticoagulant/antiphospholipid",
"      </span>",
"      antibody alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Caveats",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the results of such testing, the following observations must be kept in mind:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When a hypercoagulable workup uncovers abnormalities predisposing to VTE, the strongest risk factor for recurrence is the prior VTE event itself, particularly if idiopathic [",
"      <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Whether or not a thrombophilic condition is identified, all patients with idiopathic VTE are at substantial risk for recurrence, at least for the first few years after the event. In a randomized controlled trial and a prospective cohort study, idiopathic VTE was associated with a high rate of recurrent VTE in the absence of anticoagulation therapy that varied from 7.2 to 8.4 percent per year at follow-up of approximately two years [",
"      <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H26#H26\">",
"       \"Treatment of lower extremity deep vein thrombosis\", section on 'Idiopathic VTE'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With the exception of patients with the antiphospholipid syndrome (APS) or those with multiple hereditary prothrombotic disorders, management of patients with or without an identifiable abnormality does not differ. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link\">",
"       \"Management of inherited thrombophilia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Screening information cannot yet be used to target those requiring primary antithrombotic prophylaxis or most of those requiring extended secondary prophylaxis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TECHNICAL SCREENING ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of technical issues surrounding the screening process, including timing, effect of anticoagulants, and the specific tests to be employed. These are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Timing of screening and effect of anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important consideration in the laboratory evaluation of patients with a suspected deficiency of antithrombin, protein C, or protein S is the timing of testing. Erroneous diagnoses can be made due to the influence of acute thrombosis, comorbid illness, or anticoagulant therapy on the concentrations of these plasma proteins (",
"    <a class=\"graphic graphic_table graphicRef76966 \" href=\"UTD.htm?43/22/44396\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute thrombosis by itself can transiently reduce the plasma concentration of antithrombin and occasionally protein C and protein S.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      can produce up to a 30 percent decline in the plasma antithrombin concentration over several days.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      produces a marked reduction in the functional activity of protein C and protein S and a lesser decline in immunologic levels. Warfarin rarely elevates antithrombin concentrations in patients with antithrombin deficiency, sometimes into the normal range.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For these reasons, we recommend testing for these deficiency states at least two weeks after completing the initial three to six month course of oral anticoagulant therapy following a thrombotic event. If, however, plasma levels of antithrombin, protein C, and protein S are obtained at presentation and are well within the normal range, then a deficiency of these proteins is essentially excluded. A low concentration, on the other hand, must be confirmed by repeat testing after anticoagulation has been discontinued.",
"   </p>",
"   <p>",
"    Concerns about the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    do not apply to the second generation clotting assay for activated protein C resistance (which can be used to screen for the presence of the factor V Leiden mutation), genetic tests to detect the factor V Leiden or prothrombin gene mutations, or serologic assays for aPL.",
"   </p>",
"   <p>",
"    If an inherited thrombophilia is detected, investigation of first-degree family members should be performed to document the hereditary nature of the deficiency. Confirmation of a deficiency state in family members is also helpful in corroborating a diagnosis in patients in whom the risks of recurrent thrombosis are too great to temporarily discontinue anticoagulation. Alternatively, a diagnosis of protein C or protein S deficiency can be confirmed in the patient by testing after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    has been discontinued for two weeks under the cover of intravenous or subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or subcutaneous low molecular weight heparin at therapeutic doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Choice of coagulation tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of tests that can be performed in the workup for inherited thrombophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Practitioners may wish guidance from a coagulation specialist in the proper choices. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Arguments for screening'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We use the following as a standard approach, with the individual assays to be performed being described in more detail in the topic reviews dealing with each specific disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     APC resistance/Factor V Leiden",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both phenotyping and genotyping can be used to screen for factor V Leiden. Second generation clotting assays (ie, with factor V-deficient plasma) using an activated partial thromboplastin time-based assay are sensitive and specific for factor V Leiden. Alternatively, factor V Leiden can be easily identified by molecular analysis of genomic DNA obtained from peripheral blood mononuclear cells.",
"   </p>",
"   <p>",
"    At present, the most cost-effective approach to is to test for APC resistance using a second generation coagulation assay. Patients with low APC resistance ratios should then be genotyped for the mutation, although it can be argued that such confirmatory testing is unnecessary in laboratories that have perfect concordance between the results of their APC resistance assays and factor V Leiden genotype. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"     \"Activated protein C resistance and factor V Leiden\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Prothrombin gene mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no reliable functional assay for the mutant allele. Thus, the prothrombin 20210A mutation is detected by molecular genetic analysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=see_link\">",
"     \"Prothrombin gene mutation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Deficiency of proteins C and S",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best screening tests for deficiencies of protein C and protein S are functional assays which detect both quantitative and qualitative defects. Immunologic (antigenic) assays detect only quantitative deficiencies of these proteins. Among protein C assays, coagulation assays provide a more complete evaluation of the functional activity of the molecule than amidolytic assays. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link\">",
"     \"Protein C deficiency\"",
"    </a>",
"    .) However, coagulation assays for protein C and protein S can give falsely low values if the factor V Leiden mutation is present; as a result, reliable application of coagulation assays must initially assess whether the factor V Leiden mutation is present.",
"   </p>",
"   <p>",
"    It is important to measure free protein S antigen, since some patients with hereditary protein S deficiency have low free levels with normal or borderline total protein S levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=see_link\">",
"     \"Protein S deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     AT deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Convenient functional assays are available that measure the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    cofactor activity of antithrombin (AT). The AT-heparin cofactor assay using a factor Xa or a thrombin inhibition assay detects all currently recognized subtypes of familial AT deficiency and is therefore the best single laboratory screening test for this disorder. Distinguishing the various AT subtypes can be done by special research laboratories with an interest in antithrombin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=see_link\">",
"     \"Antithrombin (ATIII) deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Antiphospholipid antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Markers for the presence of antiphospholipid antibodies are unexplained prolongation of the activated partial thromboplastin time (aPTT) and the presence of anticardiolipin or beta2-glycoprotein I antibodies. However, neither is sufficiently sensitive nor specific to be used to establish the diagnosis. The use of additional specialized clotting assays (eg, dilute Russell viper venom time, kaolin plasma clotting time, tissue thromboplastin inhibition test) may facilitate making the diagnosis of a lupus anticoagulant.",
"   </p>",
"   <p>",
"    Some, but not all, patients with lupus anticoagulants have elevated titers of anticardiolipin or beta2-glycoprotein I antibodies and these serologic tests should be ordered in patients suspected of having this acquired defect. Patients with abnormal test results should be reevaluated, as lupus anticoagulants or elevated anticardiolipin or beta2-glycoprotein I antibody levels are generally considered to be risk factors for thrombosis only if the abnormalities persist over several months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\", section on 'The antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     JAK2 mutation screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The JAK2 mutation is found in nearly all patients with polycythemia vera and about 50 percent of those with essential thrombocythemia, conditions associated with an increased risk for thrombosis. However, routine screening for this mutation in patients with arterial thrombosis, venous thrombosis, or cerebral vein thrombosis, in the absence of splanchnic venous thrombosis (ie, Budd-Chiari syndrome or portal vein thrombosis) or overt myeloproliferative disease is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/51-55\">",
"     51-55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the myeloproliferative neoplasms\", section on 'JAK2 mutations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31575?source=see_link&amp;anchor=H3#H3\">",
"     \"Etiology of the Budd-Chiari syndrome\", section on 'Myeloproliferative disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H41#H41\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Myeloproliferative neoplasms and PNH'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated levels of several plasma coagulation factors (eg, factor VIII coagulant activity, antigenic levels of factor XI, IX, and thrombin-activatable fibrinolysis inhibitor) and occasional dysfibrinogenemias may function as independent markers of increased thrombotic risk. In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    cofactor II deficiency, plasminogen deficiency, thrombomodulin mutations, and elevations in histidine-rich glycoprotein or plasminogen activator inhibitor-1 have been considered as potential risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/41/11930/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Elevated clotting factors and chemokines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At present, we do not routinely test for these disorders in patients with thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     IDIOPATHIC VTE AND MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of malignancies associated with thromboembolic events have been previously diagnosed at the time of the thrombotic event. However, an episode of symptomatic thromboembolism can precede the diagnosis of malignancy by months to years. The yields and benefits of screening patients with idiopathic VTE for a previously undiagnosed cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link&amp;anchor=H7#H7\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Occult malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24514?source=see_link\">",
"       \"Patient information: Factor V Leiden (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"       \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16642?source=see_link\">",
"       \"Patient information: The antiphospholipid syndrome (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H703186022\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H703186105\">",
"    <span class=\"h2\">",
"     Initial approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial approach to the patient with established venous thromboembolic disease (VTE) is a two-step process:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Careful history and physical examination combined with review of imaging studies used to establish the diagnosis along with routine laboratory testing. This allows assessment of the presence and severity of the thrombotic condition and determination whether any of the acquired causes of hypercoagulability (eg, malignancy, antiphospholipid antibodies) are present. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Initial examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decide whether or not to undertake laboratory screening for the presence of hereditary or acquired thrombophilia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Screening for inherited thrombophilia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Arguments against screening'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Arguments for screening'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Technical screening issues'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H703186341\">",
"    <span class=\"h2\">",
"     How and when to screen for thrombophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;We believe that testing for an inherited thrombophilia has been prematurely adopted in routine medical practice. There is little evidence that the identification of inherited thrombophilias should influence the duration of anticoagulant therapy for patients with venous thromboembolism or that testing asymptomatic affected relatives leads to improved outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a strong family history of VTE should undergo testing for the five major inherited thrombophilic defects and their first degree relatives should be considered for screening.",
"     </li>",
"     <li>",
"      For other patients, we discuss the pros and cons of testing, explaining that their management is unlikely to be influenced by the discovery of an underlying thrombophilia. However, we take into account the desires of the patient and perhaps the referring clinician. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Suggested approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/1\">",
"      Birdwell BG, Raskob GE, Whitsett TL, et al. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med 1998; 128:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/2\">",
"      Huisman MV, B&uuml;ller HR, ten Cate JW, Vreeken J. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. The Amsterdam General Practitioner Study. N Engl J Med 1986; 314:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/3\">",
"      Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/4\">",
"      Rai R, Regan L, Hadley E, et al. Second-trimester pregnancy loss is associated with activated C resistance. Br J Haematol 1996; 92:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/5\">",
"      Sanson BJ, Friederich PW, Simioni P, et al. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 1996; 75:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/6\">",
"      Ridker PM, Miletich JP, Buring JE, et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998; 128:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/7\">",
"      Browse NL. The painful deep-vein syndrome. Lancet 1970; 1:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/8\">",
"      Sandler DA, Martin JF, Duncan JS, et al. Diagnosis of deep-vein thrombosis: comparison of clinical evaluation, ultrasound, plethysmography, and venoscan with X-ray venogram. Lancet 1984; 2:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/9\">",
"      Chait Y, Condat B, Cazals-Hatem D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 2005; 129:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/10\">",
"      Makris M, Rosendaal FR, Preston FE. Familial thrombophilia: genetic risk factors and management. J Intern Med Suppl 1997; 740:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/11\">",
"      Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997; 77:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/12\">",
"      Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/13\">",
"      Schulman S, W&aring;hlander K, Lundstr&ouml;m T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/14\">",
"      Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/15\">",
"      Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/16\">",
"      Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin G--&gt;A20210 gene variant. Ann Intern Med 1998; 129:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/17\">",
"      Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 1997; 127:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/18\">",
"      Lijfering WM, Middeldorp S, Veeger NJ, et al. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation 2010; 121:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/19\">",
"      McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/20\">",
"      Friederich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/21\">",
"      Brouwer JL, Veeger NJ, Kluin-Nelemans HC, van der Meer J. The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes. Ann Intern Med 2006; 145:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/22\">",
"      Prandoni P, Bernardi E. Upper extremity deep vein thrombosis. Curr Opin Pulm Med 1999; 5:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/23\">",
"      H&eacute;ron E, Lozinguez O, Alhenc-Gelas M, et al. Hypercoagulable states in primary upper-extremity deep vein thrombosis. Arch Intern Med 2000; 160:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/24\">",
"      Martinelli I, Cattaneo M, Panzeri D, et al. Risk factors for deep venous thrombosis of the upper extremities. Ann Intern Med 1997; 126:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/25\">",
"      Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Doggen CJ. Recurrent thrombosis and survival after a first venous thrombosis of the upper extremity. Circulation 2008; 118:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/26\">",
"      Baglin T, Gray E, Greaves M, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010; 149:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/27\">",
"      Murin S, Marelich GP, Arroliga AC, Matthay RA. Hereditary thrombophilia and venous thromboembolism. Am J Respir Crit Care Med 1998; 158:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/28\">",
"      Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? Br J Haematol 2008; 143:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/29\">",
"      Coppens M, Reijnders JH, Middeldorp S, et al. Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. J Thromb Haemost 2008; 6:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/30\">",
"      Kearon C, Julian JA, Kovacs MJ, et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood 2008; 112:4432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/31\">",
"      Hron G, Eichinger S, Weltermann A, et al. Family history for venous thromboembolism and the risk for recurrence. Am J Med 2006; 119:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/32\">",
"      Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005; 293:2352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/33\">",
"      Coppens M, van Mourik JA, Eckmann CM, et al. Current practise of testing for inherited thrombophilia. J Thromb Haemost 2007; 5:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/34\">",
"      Segal JB, Brotman DJ, Necochea AJ, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA 2009; 301:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/35\">",
"      Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:454S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/36\">",
"      Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/37\">",
"      den Heijer M, Willems HP, Blom HJ, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 2007; 109:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/38\">",
"      Bezemer ID, Doggen CJ, Vos HL, Rosendaal FR. No association between the common MTHFR 677C-&gt;T polymorphism and venous thrombosis: results from the MEGA study. Arch Intern Med 2007; 167:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/39\">",
"      Bank I, Scavenius MP, B&uuml;ller HR, Middeldorp S. Social aspects of genetic testing for factor V Leiden mutation in healthy individuals and their importance for daily practice. Thromb Res 2004; 113:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/40\">",
"      Cohn DM, Vansenne F, Kaptein AA, et al. The psychological impact of testing for thrombophilia: a systematic review. J Thromb Haemost 2008; 6:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/41\">",
"      Koeleman BP, Reitsma PH, Bertina RM. Familial thrombophilia: a complex genetic disorder. Semin Hematol 1997; 34:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/42\">",
"      Makris M, Preston FE, Beauchamp NJ, et al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost 1997; 78:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/43\">",
"      Meinardi JR, Middeldorp S, de Kam PJ, et al. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Br J Haematol 2002; 116:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/44\">",
"      Couturaud F, Kearon C, Leroyer C, et al. Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. Thromb Haemost 2006; 96:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/45\">",
"      Dalen JE. Should patients with venous thromboembolism be screened for thrombophilia? Am J Med 2008; 121:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/46\">",
"      Lijfering WM, Brouwer JL, Veeger NJ, et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 2009; 113:5314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/47\">",
"      Cohn D, Vansenne F, de Borgie C, Middeldorp S. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev 2009; :CD007069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/48\">",
"      Heijboer H, Brandjes DP, B&uuml;ller HR, et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/49\">",
"      Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001; 135:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/50\">",
"      Couturaud F, Leroyer C, Julian JA, et al. Factors that predict risk of thrombosis in relatives of patients with unprovoked venous thromboembolism. Chest 2009; 136:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/51\">",
"      Pardanani A, Lasho TL, Hussein K, et al. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. Mayo Clin Proc 2008; 83:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/52\">",
"      Austin SK, Lambert JR. The JAK2 V617F mutation and thrombosis. Br J Haematol 2008; 143:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/53\">",
"      Dentali F, Squizzato A, Appio L, et al. JAK2V617F mutation in patients with arterial thrombosis in the absence of overt myeloproliferative disease. J Thromb Haemost 2009; 7:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/54\">",
"      Dentali F, Squizzato A, Brivio L, et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 2009; 113:5617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/55\">",
"      Koopman K, Mulder AB, De Keyser J, et al. JAK2-V617F mutation in cerebral venous thrombosis. J Thromb Haemost 2009; 7:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/56\">",
"      Ohlin AK, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood 1995; 85:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/41/11930/abstract/57\">",
"      Ohlin AK, Norlund L, Marlar RA. Thrombomodulin gene variations and thromboembolic disease. Thromb Haemost 1997; 78:396.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1363 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-9D0B6BF364-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_41_11930=[""].join("\n");
var outline_f11_41_11930=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H703186022\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INITIAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical exam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SCREENING FOR INHERITED THROMBOPHILIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Multiple risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Upper extremity thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Arterial thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      When not to screen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ARGUMENTS AGAINST SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Screening for hyperhomocysteinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Additional screening issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ARGUMENTS FOR SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Suggested approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Caveats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TECHNICAL SCREENING ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Timing of screening and effect of anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Choice of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - APC resistance/Factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Prothrombin gene mutation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Deficiency of proteins C and S",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - AT deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Antiphospholipid antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - JAK2 mutation screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Other disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      IDIOPATHIC VTE AND MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H703186022\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H703186105\">",
"      Initial approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H703186341\">",
"      How and when to screen for thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1363\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1363|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/50/38694\" title=\"picture 1\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/43/30390\" title=\"picture 2\">",
"      Leukoerythroblastic blood smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1363|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/6/1132\" title=\"table 1\">",
"      Causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/42/9899\" title=\"table 2\">",
"      Prevalence thrombophil defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/18/44331\" title=\"table 3\">",
"      Risk VTE multiple defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/7/27771\" title=\"table 4\">",
"      Probability of thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/22/44396\" title=\"table 5\">",
"      Thrombophilia test interference",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=related_link\">",
"      Antithrombin (ATIII) deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24681?source=related_link\">",
"      Approach to the patient with thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14121?source=related_link\">",
"      Clinical manifestations of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=related_link\">",
"      Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=related_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24777?source=related_link\">",
"      Diagnostic approach to the patient with polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31575?source=related_link\">",
"      Etiology of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=related_link\">",
"      Obstetrical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25033?source=related_link\">",
"      Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24514?source=related_link\">",
"      Patient information: Factor V Leiden (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16642?source=related_link\">",
"      Patient information: The antiphospholipid syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=related_link\">",
"      Primary (spontaneous) upper extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=related_link\">",
"      Protein S deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=related_link\">",
"      Prothrombin gene mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=related_link\">",
"      Screening for inherited thrombophilia in asymptomatic populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_41_11931="Dx criteria pain disorder";
var content_f11_41_11931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F59089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F59089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR diagnostic criteria for pain disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         A.",
"        </strong>",
"        Pain in one or more anatomical sites is the predominant focus of the clinical presentation and is of sufficient severity to warrant clinical attention.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         B.",
"        </strong>",
"        The pain causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         C.",
"        </strong>",
"        Psychological factors are judged to have an important role in the onset, severity, exacerbation, or maintenance of the pain.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         D.",
"        </strong>",
"        The symptom or deficit is not intentionally produced or feigned (as in Factitious Disorder or Malingering).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         E.",
"        </strong>",
"        The pain is not better accounted for by a mood, anxiety, or psychotic disorder and does not meet criteria for dyspareunia.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Text Revision, Fourth Edition. Copyright &copy; 2000 American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_41_11931=[""].join("\n");
var outline_f11_41_11931=null;
var title_f11_41_11932="Clindamycin dosing for adults";
var content_f11_41_11932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dosing of clindamycin for adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Indication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose/formulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acne rosacea",
"       </td>",
"       <td>",
"        1 percent lotion, apply to affected area BID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acne vulgaris",
"       </td>",
"       <td>",
"        1 percent lotion, apply to affected area BID",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxoplasma encephalitis",
"       </td>",
"       <td>",
"        900 mg IV Q8 hours or 600 mg PO Q6 hours for 3 to",
"6 weeks, then 300-450 mg PO Q6 to 12 hours (plus pyrimethamine 50 to 75",
"mg daily)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumocystis carinii pneumonia",
"       </td>",
"       <td>",
"        900 mg IV Q8 hours initially, then 450 mg PO Q6 hours (plus primaquine 30 mg PO QD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Babesiosis",
"       </td>",
"       <td>",
"        300 to 600 mg IV or IM Q6 hours (plus quinine 650 mg Q4 to 6 hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pelvic inflammatory disease",
"       </td>",
"       <td>",
"        900 mg IV Q8 hours (plus gentamicin) followed by 450 mg PO QID for a total of 14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Bacterial vaginosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nonpregnant women",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 percent cream, one full applicator intravaginally at bedtime for 7 days; (alternative regimen) 300 mg PO BID for 7 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pregnant women",
"       </td>",
"       <td class=\"sublist_other\">",
"        300 mg PO BID for 7 days; topical cream should",
"        <strong>",
"         not",
"        </strong>",
"        be used in pregnant women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Prophylaxis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Surgical - head and neck",
"       </td>",
"       <td class=\"sublist_other\">",
"        600 mg IV 1 to 2 hours preoperatively and continued Q8 hours for 4 doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bacterial endocarditis",
"       </td>",
"       <td class=\"sublist_other\">",
"        600 mg PO 1 hour prior to the procedure or 600 mg IV within 30 minutes of the procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasmodium falciparum malaria",
"       </td>",
"       <td>",
"        (Alternative regimen) 900 mg PO TID for 3 to 5 days (plus quinine)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_41_11932=[""].join("\n");
var outline_f11_41_11932=null;
var title_f11_41_11933="Histolog classification STS III";
var content_f11_41_11933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histologic classification of soft tissue sarcomas - III",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tumors of cranial and peripheral nerves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neuroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nerve sheath ganglion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neuromuscular hamartoma (benign Triton tumor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Schwannoma (neurilemoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neurofibroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ganglioneuroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Malignant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malignant peripheral nerve sheath tumor (MPNST, neurofibrosarcoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malignant Triton tumor (MPNST with rhabdomyosarcoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malignant granular cell tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gastrointestinal autonomic nerve tumor (plexosarcoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Primitive",
"neuroectodermal tumor (PNET) (including extraskeletal Ewing sarcoma,",
"neuroblastoma, and peripheral neuroectodermal tumor [neuroepithelioma])",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Extraskeletal cartilaginous and osseous tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Soft tissue chondroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Malignant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mesenchymal chondrosarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extraskeletal osteosarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tumors of uncertain histogenesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intramuscular myxoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Juxtaarticular myxoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Deep angiomyxoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pleomorphic hyalinizing angiectatic tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ectopic hamartomatous thymoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Intermediate (rarely metastasizing)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Angiomatoid fibrous histiocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ossifying fibromyxoid tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mixed tumor/myoepithelioma/parachordoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Malignant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Synovial sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epithelioid sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alveolar soft part sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clear cell sarcoma of the soft tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extraskeletal myxoid chondrosarcoma (chordoid type)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Desmoplastic small round cell tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extrarenal rhabdoid tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malignant mesenchymoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neoplasms with perivascular epithelioid cell differentiation (PEComa)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intimal sarcoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: World Health Organization Classification of Tumours: Pathology and genetics of tumours of soft tissue and bone, Fletcher CDM, Unni KK, Mertens F, Eds. Lyon, IARC 2002 and World Health Organization Classification of Tumours: Pathology and genetics of Tumours of the nervous system, Kleihues P, Cavenee WK, Eds, Lyon, IARC, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_41_11933=[""].join("\n");
var outline_f11_41_11933=null;
var title_f11_41_11934="Support for euthanasia and PAS";
var content_f11_41_11934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Decline in support for euthanasia and PAS among American physicians",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 414px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A significant decline in support for euthanasia or PAS occurred among American oncologists between the early and late 1990s.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Emanuel, EJ, Fairclough, D, Clarridge, BR, et al, Ann Intern Med 2000; 133:537.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_41_11934=[""].join("\n");
var outline_f11_41_11934=null;
var title_f11_41_11935="Initial mgmt bact mening";
var content_f11_41_11935=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Management algorithm for adults with suspected bacterial meningitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 431px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    \"STAT\" indicates that the intervention should be done emergently.",
"    <div class=\"footnotes\">",
"     * See text and \"Dexamethasone to prevent neurologic complications of bacterial meningitis in adults\" for specific recommendations regarding the use of adjunctive dexamethasone in adults with bacterial meningitis.",
"     <br>",
"      &bull; See table \"Recommendations for empiric antimicrobial therapy for purulent meningitis based on patient age and specific predisposing condition\" (\"Empiric_abx_purulent_mening\").",
"      <br>",
"       &Delta; Administer dexamethasone and antibiotic therapy immediately after CSF is obtained.",
"       <br>",
"        &loz; See table \"Recommendations for antimicrobial therapy in adult patients with presumptive pathogen identification by positive Gram stain\" (\"Abx_for_pos_Gram_stain\").",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Tunkel, AR, Hartman, BJ, Kaplan, SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267. Copyright &copy; 2004 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_41_11935=[""].join("\n");
var outline_f11_41_11935=null;
  